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aBstRact
Advances in this century regarding allogeneic hematopoietic
stem cell transplantation (allo-HSCT) have led to an expand-
ing population of long-term survivors, many of whom suffer
severe side effects, particularly those related to graft-versus-
host disease (GVHD), a potentially multi-systemic disorder
caused by immunoeffector donor lymphocytes that destroy
host tissues. The GVHD, especially in its chronic form
(cGVHD), generates considerable morbidity and compromis-
es the physical capacity of patients. We have reviewed the
main pathophysiological aspects of the disease as well as the
data available on the effects of exercise in GVHD, based on
animal and human patient research. Although exercise train-
ing as an adjunct therapy to improve health outcomes after
allo-HSCT shows promise (particularly, this lifestyle interven-
tion can improve physical fitness and possibly immune func-
tion while attenuating fatigue), there is a need for more ran-
domized control trials that focus specifically on GVHD.
intRODUctiOn
Allogeneic hematopoietic stem cell transplant (allo-HSCT) is
the only curative option for many patients with leukemia, pri-
mary or acquired marrow failure, primary immunodeficiency
or inborn genetic diseases (378). Graft-versus-host disease
(GVHD) is a frequent complication of allo-HSCT (288), and
consists of the destruction of host tissues by donor effector
lymphocytes. The incidence of the acute form of GVHD
(aGVHD) has been estimated at 10%-80%, with symptoms
usually developing 2-3 weeks post allo-HSCT, and 30-70%
for chronic GVHD (cGVHD) in allo-HSCT recipients surviv-
ing beyond 100 days, with a median onset of 4-6 months fol-
lowing transplant (127) (see below for a definition of aGVHD
versus cGVHD). Reasons for the wide variability in the inci-
dence of both of these diseases might include individual dif-
ferences in a variety of modifiable and nonmodifiable risk
factors. These include type of conditioning regimen and
impact of regimen intensity, graft source, degree of human
leukocyte antigen (HLA) mismatch, previous donor alloim-
munization, use of total body irradiation, GVHD prophylaxis,
severity of individual organ sites, female donor–male recipi-
ent, parity of female donors, or recipient age (150, 169, 176,
244, 258, 270, 393). Mortality rates of 15-40% have been
reported for patients with aGVHD and 30-50% for those with
cGVHD (37). Reasons for the usually higher mortality rates
found in cGVHD compared with aGVHD likely include a
lower magnitude of medical advances in treatment, and the
more aggressive, multi-systemic nature of the chronic disease
form (151, 225). In addition, GVHD causes severe morbidity,
and allo-HSCT survivors with GVHD show impaired physical
and social behavior, and undergo a worse physical and psy-
chosocial recovery than survivors without this complication.
Quality of life (QoL) is thus severely compromised (119, 196,
218, 367-369).
The first-line option for the treatment of GVHD, steroid
therapy, has a failure rate of 30-40% (90). In effect, GVHD
refractory from steroids is an unresolved clinical challenge
with a high impact on both the survival and QoL of patients
(3). It is therefore imperative that researchers pursue other
effective therapies for the prevention and treatment of GVHD. 
The multi-system benefits of regular exercise have been
linked to a lower risk of numerous chronic diseases (see (114)
for an in-depth review). There is indeed strong epidemiologi-
cal evidence that this simple lifestyle intervention leads to
lower rates of all-cause mortality, cardiovascular disease,
hypertension, stroke, metabolic syndrome, type 2 diabetes,
breast cancer, colon cancer, depression, and falls (216). How-
ever, the impact exercise may have to prevent GVHD, or to
influence the course of the disease in affected patients, is
largely unknown. This paper reviews the main features of this
life-threatening disease and discusses the rationale and pre-
liminary findings supporting the effects of exercise training in
GVHD. To our knowledge, no data are available on the possi-
ble association between previous exercise habits, and the risk
or severity of GVHD.
allo-hsct and gvhD 
Allo-HSCT was first introduced to treat patients with end-
stage leukemia (381) or aplastic anemia after conventional
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treatment failure, as well as to offset the toxic effects of irradi-
ation and chemotherapy against both of these diseases (377).
The process consists of the intravenous transfer of hematopoi-
etic stem cells from a healthy donor to an immunosuppressed
recipient, to regenerate normal hematopoiesis in patients in
whom it is impaired or non-existent (379). The immunosup-
pression caused by the transplant conditioning regimen
enables the grafting of donor cells, while donor T lympho-
cytes provide anti-tumor therapy against the host’s residual
malignant cells  (graft-versus-tumor (or leukemia) (GVT)
effect) (212). However, several complications may arise dur-
ing the process. The grafted stem cells may be rejected by the
recipient (host-versus-graft (HVG) effect) or, conversely, the
donor immune system may act against the recipient (graft-ver-
sus-host (GVH) effect). The latter is clinically known as
GVHD. Such effects were discovered in studies conducted in
the mid-20th century, in which an anti-tumor cell effect of the
transplanted graft (GVT effect) was observed after allo-HSCT
(23, 24). However, in these studies, transplanted mice later
died from a second degenerative, or wasting, disease, which
caused diarrhea and weight loss, skin inflammation and liver
failure/lesions. This was the first clinical description of
aGVHD (25). 
In parallel, bone marrow transplants were conducted in
patients with malignant tumors with the objective of inducing
GVT activity without developing GVHD. This strategy was,
however, unsuccessful due to failure of the transplanted
hematopoietic stem cells (381) and was soon followed by the
technique of total body irradiation plus allogeneic bone mar-
row cell transplant. This new approach led to the first cure of
leukemia by the group of the Nobel prize winner E. Donnall
Thomas (380). Early experience was followed by further
anecdotal cases, but it was not until the mid 1970s that the
first epidemiological data of long-term survival were reported
for patients with acute leukemia subjected to allo-HSCT
(377). Since then, allo-HSCT has been widely adopted world-
wide (81) following developments made in tools designed to
assess donor-recipient synergistic and competitive interac-
tions, the selection of donors according to similarities in the
human leukocyte antigen (HLA), anti-microbial therapies,
cell transplant conditioning regimens and patient care (26,
137, 148). Allo-HSCT is also currently used as potentially
curative treatment for many different diseases (91, 107, 140,
148, 229, 339, 374). Nevertheless, today, almost 50 years after
initial studies, the challenge continues to be to maintain the
GVT effect while also facilitating the grafting of donor stem
cells, thus avoiding graft rejection and the complications of
treatment, among which GVHD is the most frequent and life-
threatening (199).
Definition and classification of gvhD
GVHD is the outcome of donor immune system cells attack-
ing the recipient’s organs (347). Donor T lymphocytes play a
major role in the pathophysiology of GVHD (109). After their
implant, donor T cells undergo activation upon alloantigen
presentation by antigen presenting cells (APCs) and then
clonally expand. Donor T cells induce damage to target
organs either directly through cytolytic attack, or indirectly
through the release of inflammatory mediators. As early as
1966, Billingham identified the necessary conditions for the
onset of GVHD (35): (i) the graft should contain immuno-
competent cells; (ii) the host should express tissue antigens
not present in the donor; and (iii) the host should be incapable
of organizing an effective destruction or inactivation response
against the transplanted cells. A fourth postulate was added
later (324): donor lymphocytes need to reach their target
organs in the host.
Figure 1. Clinical classification/differentiation of acute (aGVHD) and chronic graft-versus-host disease (cGVHD) according the US National Insti-
tutes of Health (NIH) (110).
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In 1974, Glucksberg and co-workers classified GVHD as
acute or chronic depending on its appearance before or after
day 100 after transplant, respectively. However, signs of
aGVHD may persist beyond 100 days post allo-HSCT and
those of cGVHD may commence before the 100-day time
point (397). Since then, there have been many attempts to
classify this disease and, today, the accepted system is that
created in 2005 by the US National Institutes of Health (NIH),
based on the different clinical manifestations of GVHD (63,
110, 248, 335, 349) (see also Figure 1):
1) aGVHD (lack of findings of cGVHD)
a) classic aGVHD, diagnosed before day 100 following
allo-HSCT or donor lymphocyte infusion showing
characteristics of aGVHD; 
b) persistent, recurrent or late-acute GVHD, showing
characteristic features aGVHD diagnosed after day 100
following allo-HSCT or donor lymphocyte infusion,
often after suspending immunosuppressive treatment,
lacking characteristics of cGVHD;
2) cGVHD
a) classic cGVHD, showing symptoms of cGVHD yet
lacking symptoms of aGVHD;
b) overlap GVHD syndrome, showing characteristics of
both aGVHD and cGVHD.
Pathophysiology of agvhD 
The physiopathology of aGVHD is summarized in Figure 2.
Classically, aGVHD occurs in three phases (156): 
Phase I. transplant conditioning regimen effects and
aPcs activation 
Host tissues may be damaged by the underlying disease
and/or infection before HSCT. In addition, the transplant
conditioning regimen induces damaged cells to secrete pro-
inflammatory cytokines [e.g., tumor necrosis factor (TNF)-
α, interleukin (IL)-1, IL-6] (108, 156), endogenous non-
infectious molecules known as ‘damage-associated molecu-
lar patterns’ (DAMPs) [e.g., adenosine triphosphate (ATP),
heat shock proteins or mitochondria, extracellular matrix
proteins such as biglycan] (237, 416, 435, 437) and
chemokines (77, 413). These molecules serve as “danger
signals” and are responsible for the activation of APCs,
especially dendritic cells, via toll-like receptors (TLRs) and
non-TLRs, enhancing GVHD (61, 156, 435). In the gas-
trointestinal tract, inflammatory stimuli are translocated to
the bloodstream. These signals include microbial products
(lipopolysaccharides and unmethylated cytosine-phos-
phate-guanine) or other “pathogen-associated molecular
patterns” (PAMPs), furthering the cytokine cascade (61,
155, 156). Most innate immune cells express pattern recog-
nition receptors (PRRs) and recognize PAMPs through
PRRs, such as TLRs and nucleotide-binding oligomeriza-
tion domain-like receptors. The binding of PAMPs by PRRs
on APCs activates the innate immune response, which
induces the upregulation of cytokines and MHC class II
costimulatory molecules, and promotes dendritic cell
migration to the T-cell compartment of lymph nodes so that
antigens are presented to other immune cells (77, 81, 92,
155, 156, 237, 430). 
Phase II. t lymphocyte activation
Donor T cells are recognized and activated by APCs in sec-
ondary lymph nodes (11, 81, 267) and then migrate to their
target organs where they can cause tissue damage (73, 241). 
II.1. Antigen presentation and T cell activation 
In the setting of an HLA-identical donor allo-HSCT, the
host’s APCs activate donor T lymphocytes through the pres-
entation of minor histocompatibility antigens (miHAs) by
HLA proteins to T cell receptors (14, 20, 38, 108, 139, 211,
226, 342, 348). This is the first activation signal, but costimu-
latory molecules (second signal) are needed for a full immune
response. In an HLA-non-identical allo-HSCT, aGVHD may
be induced both by CD4+ and CD8+ (class II and I major his-
tocompatibility antigen (MHC) coreceptors, respectively) due
to the miHAs disparity (108, 424). In mouse models in which
donor/recipient genetic differences are controlled for, if the
disparity between T lymphocytes and APCs affects class I
antigens, cytotoxic/suppressor CD8+ lymphocytes are activat-
ed. By contrast, if this disparity affects class II antigens, the
cells activated are cooperator CD4+ T cells (202). When T
cells are exposed to antigens in the presence of adjuvants such
as lipopolysaccharide, their migration and survival are
enhanced (104).
II.2. T lymphocyte proliferation and differentiation 
T lymphocyte activation leads to their differentiation into var-
ious T cell phenotypes such as effector, memory, regulatory or
helper (Th1, Th2, Th17), among other subsets (78, 409). Dif-
ferentiation into T helper cells is determined by the cytokines
present in the environment during the activation process (third
signal): (i) interferon (IFN)-γ (228) and IL-12 (165) promote
the development of Th1 cells, which express IFN-γ, lympho-
toxin, IL-2 and TNF-α (266); (ii) IL-4 and IL-2 promote the
development of Th2 cells (164, 215, 338, 366), which express
IL-4, IL-5, IL-9, IL-10, IL-13 and TNF-α (266); and (iii)
transforming growth factor (TGF)-β and IL-6 promote the
Th17 cell phenotype (34, 201, 240, 396) expressing IL-17A,
IL-17F, IL-22 (149, 286, 396) or IL-21 (278, 438). Th1
cytokines (IFN-γ, IL-2, TNF-α) have been correlated with
aGVHD (103, 106, 311). The balance between Th1/Th2 sub-
sets as well as other subsets such as Th17 and the production
of cytokines affects the manifestations of GVHD (432).
Although there is some controversy as how Th1/Th2 balance
might affect GVHD and various contributions of each of these
elements are still under investigation, some explanations have
been postulated, as briefly summarized below. aGVHD has
been proposed to be mediated by Th1 cells (102), whereas
Th2 cells have been reported to suppress aGVHD (208). Yet
Th2-biased donor cells deficient in signal transducer and acti-
vator of transcription 4 gene (STAT4-/-) can induce lethal
GVHD (276). On the other hand, although the absence of
Th17 cells can exacerbate aGVHD (433), Th17 cells have
been shown to augment GVHD in some circumstances (76,
185), with in vitro-generated Th17 cells mediating lung and
skin GVHD (57). Yi et al., (2009) proposed that Th1 cells can
down-regulate Th2 and Th17 cells or vice versa (432). Thus,
in the absence of IL-17 or IL-4, Th1 differentiation is aug-
mented, and tissue damage in the gut and liver is preferential-
ly exacerbated. In contrast, in the absence of IFN-γ, both Th2
and Th17 differentiation is augmented, and tissue damage in
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Figure 2. Pathophysiology of acute graft-versus-host disease (aGVHD). 
The mechanisms implicated in the pathophysiology aGVHD are summarized below. Phase I: infections, the disease itself and the conditioning
regimen damage host tissues (mostly liver, skin and intestinal mucosa). Phase II: activation of donor T cells against host antigens and subse-
quent clonal T-cell expansion. Phase III: release of inflammatory cytokines leading to further host tissue damage (104).
Symbol:             , danger signals. Abbreviations:  APC, antigen-presenting cells; CpG, unmethylated cytosine-phosphate-guanine; CTL, cytotox-
ic T lymphocytes; DAMPS, damage-associated molecular patterns; HLA, human leukocyte antigen; LPS, lipopolysaccharide; NK, natural killer;
PAMPS, pathogen-associated molecular patterns; Th1, T cell helper 1; Th2, T cell helper 2; Th17, T cell helper 17;  NK, natural killer.
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lung and skin is exacerbated (432). Absence of both IFN-γ
and IL-17 leads to further augmentation of Th2 differentiation
and exacerbated lung damage (idiopathic pneumonia) (432).
Lack of both Th1 and Th2 cells further augments Th17 differ-
entiation and exacerbates skin damage. Therefore, the balance
among Th1, Th2 and Th17 effector subsets plays an important
role in regulating T-cell immune response and, neutralizing
either Th1, Th2 or Th17 cytokines may lead to biased Th1,
Th2 or Th17 differentiation and thus can cause organ-specific
tissue damage (432).
II.3. T cell trafficking
Activated T cells migrate to secondary lymph organs and tar-
get tissues through a combination of chemokine-receptor,
selectin-ligand and integrin-ligand interactions (73, 96, 267,
268, 285, 324, 394, 405, 414, 426, 427). For example,
chemokine ligand 2 (CXCL2)-5, CCL9, CCL11, CCL17 and
CCL27 are overexpressed in the liver, spleen, skin and lungs
during aGVHD (427, 428). T cells with chemokine receptors
(CCR)3 and CCR5 cause aGVHD in the gut and liver (95,
268, 426). 
Phase III. Cellular and inflammatory effects
GVHD culminates with cytotoxic effects mediated by differ-
ent processes:
III.1. Cellular effectors 
The main cellular effectors of aGVHD are cytotoxic T lym-
phocytes and natural killer (NK) cells (182, 391). The effector
lysis mechanisms employed by cytotoxic T lymphocytes are
the pathways FAS/FASL, tumor necrosis factor-related apop-
tosis-inducing ligand (TRAIL) and perforin/granzyme B (42,
45, 46, 182, 329, 331, 391, 413, 429, 439), though other path-
ways may exist (81). 
III.2. Inflammatory effectors
Cell damage is aggravated by inflammatory mediators includ-
ing IFN-γ, TNF-α (45, 156, 300) and IL-1 (2). Microbial
products filtered by the gut mucosa trigger the production of
cytokines (156, 171). 
III.3. Other factors
Nitric oxide produced by monocytes/macrophages impairs the
cell proliferation needed for damaged epithelial tissues to heal
(206, 273). 
Pathophysiology of cgvhD
The pathophysiology of cGVHD is summarized in Figure 3.
Chronic GVHD was first described as a disease mediated by
Th2 lymphocytes (307, 372), although this idea is not fully
supported because it may be caused by Th1 cytokines (22,
111, 279, 314, 438). While several studies have revealed the
Figure 3. Pathophysiology of chronic graft-versus-host disease (cGVHD). 
The mechanisms implicated in the pathophysiology cGVHD are summarized below. First, thymic damage alters the central tolerance mecha-
nisms during immune reconstitution, producing cGVHD. Further, the thymus production of naïve regulatory T cells (Tregs) is impaired, also caus-
ing cGVHD as well as loss of peripheral tolerance. As for the implication of B cells, patients with cGVHD have high levels of B cell activating fac-
tor (BAFF), a high prevalence of auto-reactive antibodies, poor recovery of B cell levels, and prolonged immunodeficiency. Finally, fibrotic
changes also occur due to several factors such as complement factor 3 and 5, chemokines, CD4+ T lymphocytes, transforming growth factor
(TGF)-β1 and deregulation of platelet-derived growth factor (PDGF).  
Abbreviations: BAFF, B-cell activating factor; C3, complement component 3; C5, complement component 5; Tcons, conventional T cells: TGF-β,
transforming growth factor beta; Tregs, regulatory T cells; PDGF, platelet-derived growth factor.
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important role played by the Th1/Th2 balance (44, 167, 272,
276, 306, 340, 413), others suggest different cytokine profiles
depending on the disease stage (320). Th17 cells (84, 230,
277) and auto-antibodies (436) can also cause cGVHD,
though the spectrum of Th17 cells varies according to whether
the cells are classic or alternative Th17 cells (4, 86, 130, 223,
297). To some extent, the pathophysiology of cGVHD resem-
bles that of an autoimmune disease in which auto- and allo-
reactive T and B lymphocytes intervene (107). However, it
differs from the pathophysiology of aGVHD (384) and sever-
al theories for its development exist. 
Central tolerance failure. The thymus damage caused by
the conditioning regimen, aGVHD or the prophylaxis regimen
lead to dysregulation of the patient’s central tolerance mecha-
nisms during immune reconstitution following cell transplant,
giving rise to cGVHD (356). During the early recovery stage,
mature T cells obtained from the donor and expanded in a thy-
mus-independent manner are responsible for the development
of the disease. During late recovery, T cells generated de novo
from the donor’s hematopoietic stem cells through the host’s
thymus gland will condition the pathophysiology of cGVHD
(160, 203). Although the T cells produced in this way should
not attack tissues expressing autoantigens, impaired immuno-
logical tolerance to these autoantigens leads to the autoim-
mune characteristics of cGVHD (325). Although the CD4+ T
cells generated de novo from the donor stem cells seem to
Figure 4. Main clinical features of acute (aGVHD) and chronic graft-versus-host disease (cGVHD). Abbreviation: allo-HSCT, allogeneic
hematopoietic stem cell transplant. Patients with GVHD are affected at the multi-system level, which leads to a debilitated physical condition
with a subsequent decrease in the ability to cope with activities of daily living. Patients’ health status and physical condition further deteriorate
in the mid and long-term by the pharmacological treatment they receive, which induces muscle toxicity (i.e., due to high doses of immunosup-
pressant drugs). The muscle tissue also deteriorates as a result of bed rest, resulting in muscle atrophy and eventually in cachexia. All together,
these phenomena severely impair the patients’ well-being and quality of life.   
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mediate conversion from aGVHD to cGVHD (97), the latter
is also produced without being preceded by aGVHD. Howev-
er, the host’s thymus is not needed to induce cGVHD, because
autoreactive quiescent T and B cells in transplants from non-
autoimmune donors may also be activated and expanded to
cause cGVHD (436). 
Regulatory T cells (Tregs) and cGVHD. Tregs are a T-cell sub-
set marked by a CD4+ CD25hi Foxp3+ phenotype. Its deterio-
ration has been associated with peripheral tolerance loss,
autoimmunity and with cGVHD (48, 76, 436, 440). During
the lymphopenia period, thymus production of naïve Tregs is
impaired and the Tregs generated show a memory phenotype
(374). Initially Tregs undergo greater proliferation than conven-
tional T cells (Tcons), but this expansion is offset by their
greater susceptibility to apoptosis (252). This determines that
in patients who show chronic CD4+ cell reduction, the balance
Tregs/Tcons is disrupted, and this has been linked to a high inci-
dence of extensive cGVHD and peripheral tolerance loss
(252).
B lymphocytes and cGVHD. The role of B lymphocytes in
cGVHD has been identified in mice (336) and humans (55,
72, 180, 189, 190, 195, 308, 309, 403, 434), and several
authors have described the factors that affect B cell subsets in
the development of this disease (101, 259, 289, 352, 382, 436,
441). Patients with cGVHD show high levels of B cell activat-
ing factor (BAFF) (43, 59, 121, 327, 328) such that the
BAFF/B cell ratio is elevated (210, 328). Several factors have
been correlated with the presence and severity of cGVHD: a
high prevalence of autoreactive antibodies (19, 27, 43, 75, 93,
105, 121, 142, 186, 192, 249, 260, 264, 289, 304, 317, 350,
365, 373, 398, 410), the relationship among genotypes of the
Fc receptor-like 3 gene (FCRL3) (345) (335) and an increased
number of B cells strongly expressing TLR-9 (344). More-
over, these patients show poor recovery of B cell numbers and
prolonged immunodeficiency (9, 62, 101, 360, 361). Howev-
er, a return to homeostasis is essential (261) and B cell precur-
sor depletion can be a predictor of cGVHD development. In
addition, elevated numbers of these cells in the bone marrow
or an increase in naïve B and transition cells in blood can pre-
dict the success of allo-HSCT (101, 225, 328). Finally, deplet-
ed naïve B and transition cell compartments enhance the
autoreactivity of B cells with antigenic experience in these
patients (16, 172, 328). 
Fibrotic changes. Various soluble factors play a role in the
course of cGVHD.  Complement factor 3 is deposited at the
dermal-epidermal interface in patients with cGVHD (386),
and complement factor 5 has been identified as a quantitative
trait that modifies liver fibrosis (157). Chemokines have been
attributed a role in the pathogenesis of systemic sclerosis as
potent chemoattractants of leukocytes and collaborators of
pro-fibrotic cytokines (18, 275, 438). CD4+ T lymphocytes
produce fibrotic lesions in the skin, liver, exocrine glands and
thymus (1, 8, 88, 94, 126, 371, 389, 425). Elevated plasma
levels of transforming growth factor (TGF)-β1 have been cor-
related with the development of hepatic and pulmonary fibro-
sis (12, 21, 269). In addition, skin fibrosis and the overregula-
tion of TGF-β1 and mRNA for collagen have been observed
in human and murine models of scleroderma (175). In the
mouse, TGF-β has been related to sclerodermal skin changes
(82, 254), and in humans, elevated levels of this growth factor
have been detected in patients with cGVHD (227). TGF-β
plays a role in the generation and maintenance of peripheral
Tregs and in improving their suppressive actions (321). Finally,
the dysregulation of platelet-derived growth factor (PDGF)
signaling has been related to atherosclerosis, pulmonary
hypertension and fibrosis. Anti-PDGF receptor antibodies rec-
ognize the native PDGF receptor inducing tyrosine phospho-
rylation, the build-up of reactive oxygen species, the expres-
sion of collagen type I genes and conversion of the myofi-
broblast phenotype in normal human primary fibroblasts,
which leads to sclerosis (27). These antibodies have been
detected in patients with scleroderma (27) and in all patients
with extensive cGVHD (365).
clinical FeatURes
GVHD features a heterogeneous pattern of clinical presenta-
tion (see Figure 4 for a schema). The three main target organs
of aGVHD are the skin, gastrointestinal tract and liver (85,
105, 107, 122, 134, 156, 245, 255, 274, 353, 354, 400) though
the thymus (60, 207, 312, 411) and lungs (81); eyes and kid-
neys (362) may also be affected. In contrast, the clinical man-
ifestations of cGVHD resemble those observed in autoim-
mune diseases (141, 277). Although considered to be a multi-
organ disorder, initial signs of disease appear in the oral
mucosa before affecting other organs such as the skin, nails,
eyes, muscles, lungs, tendons, gut, liver, joints, nerves, serosal
surfaces, heart and immune system (79, 100, 110, 129, 141,
143, 153, 154, 204, 280, 307, 349, 350, 395).
Pharmacological treatment
All allogeneic transplant patients receive prophylaxis against
GVHD. The commonly used regimens for prevention of
aGVHD consist of a combination of a calcineurin inhibitor,
either cyclosporine-A (CsA) or tacrolimus, and an anti-
metabolite (359). However, these interventions that prevent
aGVHD are not effective in preventing cGVHD. Strategies
using anti-thymocyte globulins for in-vivo T-cell depletion
show promise but no benefit on survival (112). Despite pro-
phylaxis, many patients suffer from acute or cGVHD.
Corticosteroids (prednisone/6-methylprednisolone) are the
standard-of-care first-line treatment for both acute (158, 236,
245, 258, 393, 412) and chronic forms of GVHD (110, 153,
364, 398, 421). The treatment protocol for each patient varies
in terms of the dose, regimen and length of therapy. First-line
treatment produces a response in fewer than 50% of patients
with aGVHD and in 40–50% of patients with cGVHD
depending on initial disease severity (127). This has meant
that research efforts have been directed towards developing
additional therapies combining corticosteroids with other
agents (see table 1 for more detailed information). However,
trials performed to date have shown no benefits when other
agents are added to corticosteroids (355). Moreover, steroids
have numerous side effects (e.g., osteoporosis, osteonecrosis,
diabetes mellitus, hypertension, and can be detrimental in a
growing child), which compromise the QoL of patients (5,
120, 127, 219, 337). There is no standard second-line treat-
ment for aGVHD or cGVHD. Numerous therapeutic agents
have been assessed to treat aGVHD and cGVHD (see table 1
for more details) but no single treatment has proven better
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than others. All are associated with high failure rates and
cause severe toxic effects (127, 243, 244). The evaluation of
therapeutic options is complicated by the heterogeneous
nature of the patient group (in terms of organ involvement,
age, conditioning regimens, GVHD prophylaxis), the lack of a
clear definition of corticosteroid-refractory disease, availabili-
ty of therapies, financial considerations, inconsistent treat-
ment end points, preferences and experience of treating physi-
cians, and secondary effects of treatment. The outcome of
refractory aGVHD is poor, including a high morbidity and
mortality figures approaching 80% (90, 392). Response rates
to agents against cGVHD range from 20% to 70% (420). 
"
"
Table 1: Summary of pharmacological therapies against acute (aGVHD) and chronic graft-versus-host disease (cGVHD) 
aGVHD Refs. 
Standard of care Corticosteroids (prednisone/6-methylprednisolone (158, 236, 245, 258, 392, 393, 412) 
Etanercept (6, 41, 224, 388) 
Mycophenolate mofetil (MMF) 
Denileukin 
Pentostatin 




Antibodies against IL-2R (54, 222) 
Horse anti-thymocyte globulin (ATG) (40, 70) 
First line therapies Methylprednisolone  combined with  
either 
Mesenchymal stem cells (MSC) (187) 
ATG (15, 191, 233-235, 246, 319, 392) 
Alefacept (383) 
Alemtuzumab (Campath) (136, 250, 333, 334) 
Beclomethasone (162) 
IL2 receptor antagonists such as daclizumab (10, 217, 291, 302, 418) 
Inolimomab (32, 71, 125, 301) 
Denileukin diftitox (161, 343) 
Basiliximab (123, 251, 332, 407) 
Antitumour necrosis factor antibodies such as 
infliximab 
(67, 69, 290) 
Etanercept (7, 51, 67) 
ECP (64, 144, 293, 326, 390) 
MMF (124, 144, 146, 193, 205, 257, 293, 298) 
Sirolimus (33, 163) 
Pentostatin (40, 299) 
Alone 
MSC (99, 152, 187, 213, 214, 271, 292, 313, 401, 402, 
404) 
Horse ATG + etanercept with or without MMF (188) 
Daclizumab, infliximab and horse ATG (357) 




Daclizumab + infliximab (305) 
"
"
"cGVHD                                          Refs. 
First line therapies Corticosteroids alone or combined with: 








Extracorporeal photophoresis (ECP) 
(17, 198, 363, 364) 
(17, 197) 
(46, 58, 308) 
(50, 231, 247) 
(40, 135) 
(72, 403, 434) 
(133) 
(133) 






Oral beclomethasone (162) 
Hydroxychloroquine (133) 
Thalidomide (47, 209, 287, 318, 399) 
Clofazimine (221, 323) 
Cyclophosphamide (303) 
Steroid pulse (5) 
Sirolimus (69, 180, 181) 
ECP (13, 36, 39, 53, 66, 80, 83, 117, 118, 128, 138, 145, 
147, 183, 184, 257, 284, 294-296, 316, 326, 330, 
337, 390) 
Imatinib (238, 239, 265, 282, 283, 358) 
MMF (28, 29, 50, 52, 124, 193, 205, 220, 231, 263) 
Rituximab (55, 56, 72, 190, 195, 262, 281, 308, 309, 346, 370, 
375, 403, 434) 
mTOR inhibitor (178, 310) 
MSC (415) 
Thoracoabdominal irradiation (49) 
Pentostatin (173, 174, 299) 
Retinoids (Am80, etretinate/isotretinoin) (242, 277) 
Calcineurin inhibitors (58, 387) 
Alone 
MTX (87, 132, 166, 168, 179) 
Prednisone + MMF + sirolimus or ECP (50, 68, 117, 147, 180, 231) 
Isotretinoin + PUVA (131) 












88 •   Graft-versus-host disease and exercise
EIR 21 2015
non-pharmacological treatment:
rationale for exercise interventions
Clearly there is an urgent clinical requirement to optimize cur-
rent therapies and develop novel treatments for GVHD based
on the patient’s individual needs. The heterogeneous nature of
its manifestations calls for a multidisciplinary approach to
patient management including input from physiotherapists,
microbiologists, occupational therapists, dieticians, pharma-
cists and psychologists. There is strong epidemiological evi-
dence that regular physical exercise (e.g., brisk walking, jog-
ging) leads to a lower risk of all-cause mortality, cardiovascular
disease, hypertension, stroke, metabolic syndrome, type 2 dia-
betes, breast cancer, colon cancer, depression and falls (216).
Exercise has therapeutic benefits on many systems in the body
because working skeletal muscles produce numerous secreted
factors (‘myokines’) with potential drug-like effects such as IL-
6 (an anti-inflammatory cytokine when released during exer-
tion), secreted protein acidic and rich in cysteine (SPARC) or
calprotectin (with potential anti-tumorigenic effects) (see
Fiuza-Luces et al. for an extensive review (114)). Exercise also
stimulates the release of stem cells with a strong regenerative
potential from their source of origin (e.g., bone marrow) to the
bloodstream (114). Moreover, the beneficial effects of moder-
ate-intensity exercise on immune function, at least in non-
immunocompromised individuals, have been well established
(406). Because regular physical exercise has positive effects on
the chain of interactive events that occur from the time of cen-
tral nervous system stimulation to skeletal muscle contraction,
it increases a person’s ability to cope with activities of daily liv-
ing, and improves cardiorespiratory capacity (commonly
expressed as peak oxygen uptake, VO2peak) in virtually all
population groups (232). Finally, exercise is a lifestyle inter-
vention that is also recommended for all patient groups, includ-
ing children and adult recipients of HSCT (423). Thus, it is of
medical interest to assess the effects of exercise in GVHD.
exercise interventions in gvhD (i):
Murine model studies
The present authors sought to determine the effects of a moder-
ate-intensity exercise (treadmill running) program on GVHD in
mouse models of aGVHD (115) and cGVHD (113, 115, 116).
No other data are available on exercise and murine models of
GVHD. In one our studies (115), we addressed the effects of
exercise (treadmill running) in the absence of CsA or any
immunosuppressive treatment in a murine model of aGVHD
and one of cGVHD. In the setting of aGVHD, mice subjected
to 12 weeks of training showed an improved functional capaci-
ty and clinical course of disease relative to controls. At the
muscle level, these mice featured higher citrate synthase activi-
ty (a classic indicator of mitochondrial oxidative capacity),
although no effects were detected on the phospho-p70 S6
kinase/p70 S6 kinase ratio (an indicator of muscle anabolic
state). However, both experimental animals and controls
showed a similar response throughout the study in terms of
rates of survival, immune cell recovery, systemic inflammation
and target organ (skin, liver, intestine) damage. In the cGVHD
model, the exercise group showed less worsening of physical
capacity, accompanied by increases in citrate synthase activity.
In addition, immune recovery was unmodified, such that no
detrimental effects were produced on the GVT effect or on
infections provoked by the immunocompromised state of the
mice. These benefits did not appear to be linked to a possible
anti-inflammatory effect of exercise, though reduced IL-6 lev-
els were recorded in the exercise intervention group. However,
the exercise intervention failed to affect variables such as sur-
vival, disease progression or target organ histological findings. 
In another of our studies (116), we reported our analysis of
the effects of exercise added to the standard immunosuppres-
sive therapy used for this disease (CsA) in the same murine
model of cGVHD. Mice in the intervention group showed sig-
nificantly higher survival rates, a reduced resting heart rate (an
indicator of cardiovascular fitness), and an improved disease
course compared to control animals. Further, the exercise pro-
gram led to lower TNF-α and IL-4 levels, reflecting a weaker
inflammatory state. Immune reconstitution was improved, with
expanded B lymphocytes and CD4 T lymphocyte compart-
ments. At the muscle tissue level, citrate synthase, respiratory
chain complex activities and the phospho-p70 S6 kinase/p70
S6 kinase ratio failed to show an improvement with exercise
training, probably due to the detrimental muscle effects of CsA.
Finally, similar histological observations were made in the dis-
ease's target organs in mice surviving the study period.  
In another study (113), we examined the role of autophagy as
a possible mechanism for cardiac adaptations produced in
response to exercise in mice with cGVHD that survived until the
end of the study described above (116). Autophagy is an intracel-
lular quality control mechanism of degradation and recycling of
damaged macromolecules and organelles that is currently gaining
attention because of its potential involvement in longevity and
defense against chronic diseases. After 12 weeks of training, lev-
els of several markers of autophagy (autophagy related gene 12
(Atg12), microtubule-associated protein 1 light chain 3 alpha
(LC3B), unc-51-like kinase 1 phosphorylated at serine 555
(phospho-ULK1 S555) and sequestosome 1 (SQSTM1/p62),
were elevated, as were the activities of the antioxidant enzymes
catalase and glutathione reductase relative to those recorded in
control mice. These benefits of exercise were observed in the
absence of modifications to the proteins involved in mitochondri-
al dynamics and heart muscle contraction, and thus failed to
affect cardiac structure and function. No significant differences
were detected in control and experimental animals in terms of
electron transport chain complexes or citrate synthase activity. 
exercise interventions in gvhD (ii):
human studies
Patients experience considerable levels of physical and psy-
chological distress before, during and after allo-HSCT. In
addition to GVHD, muscle atrophy, decrements in physical
performance, cachexia, pneumonia, psychological impair-
ments and mortality are more pronounced in the allogeneic
compared to the autologous transplant setting (159, 200, 408,
431). Physical exercise has recently been purported to amelio-
rate some of these treatment-related side effects and enhance
the rehabilitation process in allo-HSCT patients (419).
Despite this, however, no research effort to date has character-
ized the effects of exercise in patients with GVHD. Existing
exercise training interventions have targeted patients undergo-
ing allo-HSCT, among whom patients with GVHD have
sometimes been included (table 2 see next side). Among the
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beneficial effects of exercise reported in these studies were
positive effects on QoL (30, 177, 419), improvements in
endurance/aerobic capacity (30, 31, 74, 177, 419), muscular
strength (30, 31, 74, 177, 256, 419), functional capacity (30,
177), and perceptions of fatigue, physical emotional and
social well-being (419). Exercise training has also been
shown to reduce perceived pain scores and subdue anxiety,
depression and aggressive or hostile behavior (419). Although
the patient cohorts and experimental designs employed in
these studies were very heterogeneous, both aerobic and
resistance based exercise appeared to positively influence var-
ious outcomes in allo-HSCT inpatients, as well as outpatients. 
The vast majority of studies that have examined the effects
of exercise after allo-HSCT have involved inpatient cohorts
(table 2 see next side). In a small retrospective study of allo-
HSCT patients that received myeloablative conditioning regi-
mens (i.e., chemotherapy, irradiation), an inverse correlation
was found between the level of physical activity performed
during hospitalization (number of steps taken daily by the
patient) and time to discharge (170). This relationship was
observed regardless of whether or not the patient experienced
GVHD, infections or cytomegalovirus reactivation. Interest-
ingly, however, physical activity did not impact the length of
hospitalization in patients receiving non-myeloablative condi-
tioning regimens.
Exercise training studies involving allo-HSCT outpatients
are relatively uncommon. A home-based aerobic exercise
training intervention was administered to cancer survivors (at
least 6-months post allo-HSCT), although only ~31% of these
patients received an allo-transplant (417). Patients performed
20-40 minutes of activity at 40-60% of predicted heart rate
reserve 3 to 5 times per week for 12 weeks. Although lacking
a control group, scores on aerobic fitness, fatigue severity and
physical well-being improved after exercise training, with no
adverse events being reported. Another study involving allo-
HSCT outpatients (385) enrolled 10 patients with severe
cGVHD and bronchiolitis obliterans syndrome, which is the
most common and serious pulmonary complication of
cGVHD (63, 65). The 8-week pulmonary rehabilitation pro-
gram, which involved both strength and aerobic based exer-
cise session ~3 times per week, improved 6-minute walk dis-
tance, exercise tolerance, subjective symptoms of dyspnea
and QoL scores (385). To our knowledge this is the only study
conducted to date in which all participants had some form of
GVHD (385).
The diverse nature of the exercise training studies involv-
ing allo-HSCT patients makes it difficult to draw any firm
conclusions pertaining to how physical exercise may benefit a
patient with GVHD. Although no study reported an adverse
event as a direct result of testing or exercising, safety issues or
the feasibility of performing exercise training interventions in
patients with GVHD were not clearly confirmed in most of
these studies. Combining these studies is challenging due to
study limitations and the disparate nature of the patient
cohorts and experimental designs. These include small sample
sizes, a wide range of different outcomes and measurements,
varying types of interventions, different starting and end
points, the duration, frequency and intensity of the different
exercise components, different proportions and severity of
GVHD patients, the presence or absence of a control group, or
varying standard care regimes used in controls, among others.
Although exercise training shows promise, there is a critical
need for more randomized clinical trials to determine if exer-
cise is capable of ameliorating the detrimental effects of both
acute and cGVHD in humans. Although exercise has been
shown to have profound immunologic effects and GVHD is
primarily an immunoreactive disorder, it is surprising that
very few studies have focused on the effects of exercise on
immunological outcomes in the allogeneic transplant setting.
In one randomized control trial involving allogeneic bone
marrow transplant patients, a series of bed exercises (per-
formed 30 minutes daily for 6-weeks) increased total lympho-
cyte counts by 40.9 cells/μl compared to a decrease of 640.7
cells/μl in the non-exercising control group (194), without
affecting the composition of CD4+ and CD8+ T-cell subsets.
As immune reconstitution is a major determinant of prognosis
and progression-free survival after allo-HSCT (89, 376), fur-
ther randomized control trials exploring the effects of exercise
training on immune reconstitution against viruses and tumors
in patients with both acute and cGVHD would be illuminat-
ing.
cOnclUsiOn
Since exercise training as an adjunct therapy to improve
health outcomes after allo-HSCT shows promise, there is a
critical need for more randomized control trials that focus
specifically on GVHD. While outcome measures such as hos-
pitalization time, exercise tolerance, physical functioning and
emotional and social well-being are all important, there is also
a need to explore potential mechanisms underpinning the ben-
eficial effects of exercise. For instance, it remains to be seen
in human models of GVHD if exercise training can alter
cytokine profiles and regulatory T-cell function, improve
immune reconstitution to viruses and tumors, or dampen the
activity of alloreactive T-cells. 
acKnOwleDgMents
Fiuza-Luces C. is supported by a Sara Borrell contract (file
number CD14/00005) from the Institute of Health Carlos III
(ISCIII), the main Public Research Entity funding, managing
and carrying out biomedical research in Spain. The ISCIII
reports directly to the Ministry of Economy and Competitive-
ness and in operational terms to both this Ministry and to the
Ministry of Health, Social Services and Equality.






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































  @  #
















































































































































































































































































































































































































































































































































































































































































































































































































  < #















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































  < 



































































































































































































































































































































































































































































































































































































































































































































































































   #'

#  









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































  '   <      #

    #'























































































































































































































































































































































































































































































































































































































   #































































































































































































































































































































   



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































   #




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Graft-versus-host disease and exercise •   95
EIR 21 2015
ReFeRences
1. Abbott KL, Friday BB, Thaloor D, Murphy TJ, and Pavlath
GK. Activation and cellular localization of the cyclosporine A-
sensitive transcription factor NF-AT in skeletal muscle cells.
Molecular biology of the cell 9: 2905-2916, 1998.
2. Abhyankar S, Gilliland DG, and Ferrara JL. Interleukin-1 is a
critical effector molecule during cytokine dysregulation in
graft versus host disease to minor histocompatibility antigens.
Transplantation 56: 1518-1523, 1993.
3. Abu-Dalle I, Reljic T, Nishihori T, Antar A, Bazarbachi A,
Djulbegovic B, Kumar A, and Kharfan-Dabaja MA. Extracor-
poreal Photopheresis in Steroid-Refractory Acute or Chronic
Graft-versus-Host Disease: Results of a Systematic Review of
Prospective Studies. Biology of blood and marrow transplanta-
tion : journal of the American Society for Blood and Marrow
Transplantation 2014.
4. Ahern PP, Schiering C, Buonocore S, McGeachy MJ, Cua DJ,
Maloy KJ, and Powrie F. Interleukin-23 drives intestinal
inflammation through direct activity on T cells. Immunity 33:
279-288, 2010.
5. Akpek G, Lee SM, Anders V, and Vogelsang GB. A high-dose
pulse steroid regimen for controlling active chronic graft-ver-
sus-host disease. Biology of blood and marrow transplantation
: journal of the American Society for Blood and Marrow
Transplantation 7: 495-502, 2001.
6. Alousi AM, Uberti J, and Ratanatharathorn V. The role of B
cell depleting therapy in graft versus host disease after allo-
geneic hematopoietic cell transplant. Leukemia & lymphoma
51: 376-389, 2010.
7. Alousi AM, Weisdorf DJ, Logan BR, Bolanos-Meade J, Carter
S, Difronzo N, Pasquini M, Goldstein SC, Ho VT, Hayes-Lat-
tin B, Wingard JR, Horowitz MM, Levine JE, Blood, and Mar-
row Transplant Clinical Trials N. Etanercept, mycophenolate,
denileukin, or pentostatin plus corticosteroids for acute graft-
versus-host disease: a randomized phase 2 trial from the Blood
and Marrow Transplant Clinical Trials Network. Blood 114:
511-517, 2009.
8. Allen RD, Staley TA, and Sidman CL. Differential cytokine
expression in acute and chronic murine graft-versus-host-dis-
ease. European journal of immunology 23: 333-337, 1993.
9. Allman DM, Ferguson SE, Lentz VM, and Cancro MP. Periph-
eral B cell maturation. II. Heat-stable antigen(hi) splenic B
cells are an immature developmental intermediate in the pro-
duction of long-lived marrow-derived B cells. Journal of
immunology 151: 4431-4444, 1993.
10. Anasetti C, Hansen JA, Waldmann TA, Appelbaum FR, Davis
J, Deeg HJ, Doney K, Martin PJ, Nash R, Storb R, and et al.
Treatment of acute graft-versus-host disease with humanized
anti-Tac: an antibody that binds to the interleukin-2 receptor.
Blood 84: 1320-1327, 1994.
11. Anderson BE, Taylor PA, McNiff JM, Jain D, Demetris AJ,
Panoskaltsis-Mortari A, Ager A, Blazar BR, Shlomchik WD,
and Shlomchik MJ. Effects of donor T-cell trafficking and prim-
ing site on graft-versus-host disease induction by naive and
memory phenotype CD4 T cells. Blood 111: 5242-5251, 2008.
12. Anscher MS, Peters WP, Reisenbichler H, Petros WP, and Jir-
tle RL. Transforming growth factor beta as a predictor of liver
and lung fibrosis after autologous bone marrow transplantation
for advanced breast cancer. The New England journal of medi-
cine 328: 1592-1598, 1993.
13. Apisarnthanarax N, Donato M, Korbling M, Couriel D,
Gajewski J, Giralt S, Khouri I, Hosing C, Champlin R, Duvic
M, and Anderlini P. Extracorporeal photopheresis therapy in
the management of steroid-refractory or steroid-dependent
cutaneous chronic graft-versus-host disease after allogeneic
stem cell transplantation: feasibility and results. Bone marrow
transplantation 31: 459-465, 2003.
14. Appleman LJ, and Boussiotis VA. T cell anergy and costimula-
tion. Immunological reviews 192: 161-180, 2003.
15. Arai S, Margolis J, Zahurak M, Anders V, and Vogelsang GB.
Poor outcome in steroid-refractory graft-versus-host disease
with antithymocyte globulin treatment. Biology of blood and
marrow transplantation : journal of the American Society for
Blood and Marrow Transplantation 8: 155-160, 2002.
16. Arce E, Jackson DG, Gill MA, Bennett LB, Banchereau J, and
Pascual V. Increased frequency of pre-germinal center B cells
and plasma cell precursors in the blood of children with sys-
temic lupus erythematosus. Journal of immunology 167: 2361-
2369, 2001.
17. Arora M, Wagner JE, Davies SM, Blazar BR, Defor T, Enright
H, Miller WJ, and Weisdorf DF. Randomized clinical trial of
thalidomide, cyclosporine, and prednisone versus cyclosporine
and prednisone as initial therapy for chronic graft-versus-host
disease. Biology of blood and marrow transplantation : journal
of the American Society for Blood and Marrow Transplanta-
tion 7: 265-273, 2001.
18. Atamas SP, and White B. The role of chemokines in the patho-
genesis of scleroderma. Current opinion in rheumatology 15:
772-777, 2003.
19. Baird K, Cooke K, and Schultz KR. Chronic graft-versus-host
disease (GVHD) in children. Pediatric clinics of North Ameri-
ca 57: 297-322, 2010.
20. Banchereau J, and Steinman RM. Dendritic cells and the con-
trol of immunity. Nature 392: 245-252, 1998.
21. Banovic T, MacDonald KP, Morris ES, Rowe V, Kuns R, Don
A, Kelly J, Ledbetter S, Clouston AD, and Hill GR. TGF-beta
in allogeneic stem cell transplantation: friend or foe? Blood
106: 2206-2214, 2005.
22. Barak V, Levi-Schaffer F, Nisman B, and Nagler A. Cytokine
dysregulation in chronic graft versus host disease. Leukemia &
lymphoma 17: 169-173, 1995.
23. Barnes DW, Corp MJ, Loutit JF, and Neal FE. Treatment of
murine leukaemia with X rays and homologous bone marrow;
preliminary communication. British medical journal 2: 626-
627, 1956.
24. Barnes DW, and Loutit JF. Treatment of murine leukaemia
with x-rays and homologous bone marrow. II. British journal
of haematology 3: 241-252, 1957.
25. Barnes DW, Loutit JF, and Micklem HS. "Secondary disease" of
radiation chimeras: a syndrome due to lymphoid aplasia. Annals
of the New York Academy of Sciences 99: 374-385, 1962.
26. Baron C, Somogyi R, Greller LD, Rineau V, Wilkinson P, Cho
CR, Cameron MJ, Kelvin DJ, Chagnon P, Roy DC, Busque L,
Sekaly RP, and Perreault C. Prediction of graft-versus-host
disease in humans by donor gene-expression profiling. PLoS
medicine 4: e23, 2007.
27. Baroni SS, Santillo M, Bevilacqua F, Luchetti M, Spadoni T,
Mancini M, Fraticelli P, Sambo P, Funaro A, Kazlauskas A,
Avvedimento EV, and Gabrielli A. Stimulatory autoantibodies
to the PDGF receptor in systemic sclerosis. The New England
journal of medicine 354: 2667-2676, 2006.
96 •   Graft-versus-host disease and exercise
EIR 21 2015
28. Basara N, Blau WI, Romer E, Rudolphi M, Bischoff M,
Kirsten D, Sanchez H, Gunzelmann S, and Fauser AA.
Mycophenolate mofetil for the treatment of acute and chronic
GVHD in bone marrow transplant patients. Bone marrow
transplantation 22: 61-65, 1998.
29. Baudard M, Vincent A, Moreau P, Kergueris MF, Harousseau
JL, and Milpied N. Mycophenolate mofetil for the treatment of
acute and chronic GVHD is effective and well tolerated but
induces a high risk of infectious complications: a series of 21
BM or PBSC transplant patients. Bone marrow transplantation
30: 287-295, 2002.
30. Baumann FT, Kraut L, Schule K, Bloch W, and Fauser AA. A
controlled randomized study examining the effects of exercise
therapy on patients undergoing haematopoietic stem cell trans-
plantation. Bone marrow transplantation 45: 355-362, 2010.
31. Baumann FT, Zopf EM, Nykamp E, Kraut L, Schule K, Elter
T, Fauser AA, and Bloch W. Physical activity for patients
undergoing an allogeneic hematopoietic stem cell transplanta-
tion: benefits of a moderate exercise intervention. European
journal of haematology 87: 148-156, 2011.
32. Bay JO, Dhedin N, Goerner M, Vannier JP, Marie-Cardine A,
Stamatoullas A, Jouet JP, Yakoub-Agha I, Tabrizi R, Faucher
C, Diez-Martin JL, Nunez G, Parody R, Milpied N, Esperou
H, Garban F, Galambrun C, Kwiatkovski F, Darlavoix I, Zinai
A, Fischer A, Michallet M, and Vernant JP. Inolimomab in
steroid-refractory acute graft-versus-host disease following
allogeneic hematopoietic stem cell transplantation: retrospec-
tive analysis and comparison with other interleukin-2 receptor
antibodies. Transplantation 80: 782-788, 2005.
33. Benito AI, Furlong T, Martin PJ, Anasetti C, Appelbaum FR,
Doney K, Nash RA, Papayannopoulou T, Storb R, Sullivan
KM, Witherspoon R, and Deeg HJ. Sirolimus (rapamycin) for
the treatment of steroid-refractory acute graft-versus-host dis-
ease. Transplantation 72: 1924-1929, 2001.
34. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M,
Weiner HL, and Kuchroo VK. Reciprocal developmental path-
ways for the generation of pathogenic effector TH17 and regu-
latory T cells. Nature 441: 235-238, 2006.
35. Billingham RE. The biology of graft-versus-host reactions.
Harvey lectures 62: 21-78, 1966.
36. Bisaccia E, Palangio M, Gonzalez J, Adler KR, Rowley SD,
and Goldberg SL. Treating refractory chronic graft-versus-host
disease with extracorporeal photochemotherapy. Bone marrow
transplantation 31: 291-294, 2003.
37. Blazar BR, Murphy WJ, and Abedi M. Advances in graft-ver-
sus-host disease biology and therapy. Nature reviews
Immunology 12: 443-458, 2012.
38. Bleakley M, and Riddell SR. Exploiting T cells specific for
human minor histocompatibility antigens for therapy of
leukemia. Immunology and cell biology 89: 396-407, 2011.
39. Bojanic I, Serventi Seiwerth R, Golubic Cepulic B, Mazic S,
Lukic M, Raos M, Plenkovic F, Golemovic M, Dubravcic K,
Perkovic S, Batinic D, and Labar B. Treatment of chronic
GVHD with extracorporeal photochemotherapy. Transfusion
and apheresis science : official journal of the World Apheresis
Association : official journal of the European Society for
Haemapheresis 48: 193-194, 2013.
40. Bolanos-Meade J, Jacobsohn DA, Margolis J, Ogden A, Wien-
tjes MG, Byrd JC, Lucas DM, Anders V, Phelps M, Grever
MR, and Vogelsang GB. Pentostatin in steroid-refractory acute
graft-versus-host disease. Journal of clinical oncology : offi-
cial journal of the American Society of Clinical Oncology 23:
2661-2668, 2005.
41. Bolanos-Meade J, Wu J, Logan BR, Levine JE, Ho VT, Alousi
AM, Weisdorf DJ, Luznik L, Blood, and Marrow Transplant
Clinical Trials N. Lymphocyte phenotype during therapy for
acute graft-versus-host disease: a brief report from BMT-CTN
0302. Biology of blood and marrow transplantation : journal
of the American Society for Blood and Marrow Transplanta-
tion 19: 481-485, 2013.
42. Braun MY, Lowin B, French L, Acha-Orbea H, and Tschopp J.
Cytotoxic T cells deficient in both functional fas ligand and
perforin show residual cytolytic activity yet lose their capacity
to induce lethal acute graft-versus-host disease. The Journal of
experimental medicine 183: 657-661, 1996.
43. Brink R. Regulation of B cell self-tolerance by BAFF. Semi-
nars in immunology 18: 276-283, 2006.
44. Broady R, Yu J, Chow V, Tantiworawit A, Kang C, Berg K,
Martinka M, Ghoreishi M, Dutz J, and Levings MK. Cuta-
neous GVHD is associated with the expansion of tissue-local-
ized Th1 and not Th17 cells. Blood 116: 5748-5751, 2010.
45. Brown GR, Lee E, and Thiele DL. TNF-TNFR2 interactions
are critical for the development of intestinal graft-versus-host
disease in MHC class II-disparate (C57BL/6J-->C57BL/6J x
bm12)F1 mice. Journal of immunology 168: 3065-3071, 2002.
46. Brown GR, Lee EL, El-Hayek J, Kintner K, and Luck C. IL-
12-independent LIGHT signaling enhances MHC class II dis-
parate CD4+ T cell alloproliferation, IFN-gamma responses,
and intestinal graft-versus-host disease. Journal of immunolo-
gy 174: 4688-4695, 2005.
47. Browne PV, Weisdorf DJ, DeFor T, Miller WJ, Davies SM,
Filipovich A, McGlave PB, Ramsay NK, Wagner J, and
Enright H. Response to thalidomide therapy in refractory
chronic graft-versus-host disease. Bone marrow transplanta-
tion 26: 865-869, 2000.
48. Buckner JH. Mechanisms of impaired regulation by
CD4(+)CD25(+)FOXP3(+) regulatory T cells in human
autoimmune diseases. Nature reviews Immunology 10: 849-
859, 2010.
49. Bullorsky EO, Shanley CM, Stemmelin GR, Musso A, Rabi-
novich O, Ceresetto J, and Quiroga L. Total lymphoid irradia-
tion for treatment of drug resistant chronic GVHD. Bone mar-
row transplantation 11: 75-76, 1993.
50. Busca A, Locatelli F, Marmont F, Audisio E, and Falda M.
Response to mycophenolate mofetil therapy in refractory
chronic graft-versus-host disease. Haematologica 88: 837-839,
2003.
51. Busca A, Locatelli F, Marmont F, Ceretto C, and Falda M.
Recombinant human soluble tumor necrosis factor receptor
fusion protein as treatment for steroid refractory graft-versus-
host disease following allogeneic hematopoietic stem cell
transplantation. American journal of hematology 82: 45-52,
2007.
52. Busca A, Saroglia EM, Lanino E, Manfredini L, Uderzo C,
Nicolini B, Messina C, Rabusin M, and Miniero R. Mycophe-
nolate mofetil (MMF) as therapy for refractory chronic GVHD
(cGVHD) in children receiving bone marrow transplantation.
Bone marrow transplantation 25: 1067-1071, 2000.
53. Bykova TA, Kozlov AV, Stancheva NV, Semenova EV, Kulag-
ina, II, Bondarenko SN, Vavilov VN, Morozova EV,
Zubarovskaia LS, and Afanas'ev BV. [Extracorporeal photo-
pheresis in the treatment of patients with refractory chronic
Graft-versus-host disease and exercise •   97
EIR 21 2015
graft-versus-host disease after allogeneic bone marrow trans-
plantation]. Terapevticheskii arkhiv 85: 60-68, 2013.
54. Cahn JY, Bordigoni P, Tiberghien P, Milpied N, Brion A, Wid-
jenes J, Lioure B, Michel G, Burdach S, Kolb HJ, and et al.
Treatment of acute graft-versus-host disease with methylpred-
nisolone and cyclosporine with or without an anti-interleukin-
2 receptor monoclonal antibody. A multicenter phase III study.
Transplantation 60: 939-942, 1995.
55. Canninga-van Dijk MR, van der Straaten HM, Fijnheer R,
Sanders CJ, van den Tweel JG, and Verdonck LF. Anti-CD20
monoclonal antibody treatment in 6 patients with therapy-
refractory chronic graft-versus-host disease. Blood 104: 2603-
2606, 2004.
56. Carella AM, Biasco S, Nati S, Congiu A, and Lerma E. Ritux-
imab is effective for extensive steroid-refractory chronic graft-
vs.-host-disease. Leukemia & lymphoma 48: 623-624, 2007.
57. Carlson MJ, West ML, Coghill JM, Panoskaltsis-Mortari A,
Blazar BR, and Serody JS. In vitro-differentiated TH17 cells
mediate lethal acute graft-versus-host disease with severe
cutaneous and pulmonary pathologic manifestations. Blood
113: 1365-1374, 2009.
58. Carnevale-Schianca F, Martin P, Sullivan K, Flowers M, Gooley
T, Anasetti C, Deeg J, Furlong T, McSweeney P, Storb R, and
Nash RA. Changing from cyclosporine to tacrolimus as salvage
therapy for chronic graft-versus-host disease. Biology of blood
and marrow transplantation : journal of the American Society
for Blood and Marrow Transplantation 6: 613-620, 2000.
59. Clark WB, Brown-Gentry KD, Crawford DC, Fan KH, Snave-
ly J, Chen H, Savani BN, Kassim A, Greer JP, Schuening FG,
Engelhardt BG, and Jagasia MH. Genetic variation in recipient
B-cell activating factor modulates phenotype of GVHD. Blood
118: 1140-1144, 2011.
60. Clave E, Busson M, Douay C, Peffault de Latour R, Berrou J,
Rabian C, Carmagnat M, Rocha V, Charron D, Socie G, and
Toubert A. Acute graft-versus-host disease transiently impairs
thymic output in young patients after allogeneic hematopoietic
stem cell transplantation. Blood 113: 6477-6484, 2009.
61. Cooke KR, Hill GR, Crawford JM, Bungard D, Brinson YS,
Delmonte J, Jr., and Ferrara JL. Tumor necrosis factor- alpha
production to lipopolysaccharide stimulation by donor cells pre-
dicts the severity of experimental acute graft-versus-host dis-
ease. The Journal of clinical investigation 102: 1882-1891, 1998.
62. Corre E, Carmagnat M, Busson M, de Latour RP, Robin M,
Ribaud P, Toubert A, Rabian C, and Socie G. Long-term
immune deficiency after allogeneic stem cell transplantation:
B-cell deficiency is associated with late infections. Haemato-
logica 95: 1025-1029, 2010.
63. Couriel D, Carpenter PA, Cutler C, Bolanos-Meade J, Treister
NS, Gea-Banacloche J, Shaughnessy P, Hymes S, Kim S,
Wayne AS, Chien JW, Neumann J, Mitchell S, Syrjala K,
Moravec CK, Abramovitz L, Liebermann J, Berger A, Gerber
L, Schubert M, Filipovich AH, Weisdorf D, Schubert MM,
Shulman H, Schultz K, Mittelman B, Pavletic S, Vogelsang
GB, Martin PJ, Lee SJ, and Flowers ME. Ancillary therapy
and supportive care of chronic graft-versus-host disease:
national institutes of health consensus development project on
criteria for clinical trials in chronic Graft-versus-host disease:
V. Ancillary Therapy and Supportive Care Working Group
Report. Biology of blood and marrow transplantation : journal
of the American Society for Blood and Marrow Transplanta-
tion 12: 375-396, 2006.
64. Couriel D, Hosing C, Saliba R, Shpall EJ, Andelini P, Popat U,
Donato M, and Champlin R. Extracorporeal photopheresis for
acute and chronic graft-versus-host disease: does it work?
Biology of blood and marrow transplantation : journal of the
American Society for Blood and Marrow Transplantation 12:
37-40, 2006.
65. Couriel DR. Ancillary and supportive care in chronic graft-
versus-host disease. Best practice & research Clinical haema-
tology 21: 291-307, 2008.
66. Couriel DR, Hosing C, Saliba R, Shpall EJ, Anderlini P,
Rhodes B, Smith V, Khouri I, Giralt S, de Lima M, Hsu Y,
Ghosh S, Neumann J, Andersson B, Qazilbash M, Hymes S,
Kim S, Champlin R, and Donato M. Extracorporeal pho-
tochemotherapy for the treatment of steroid-resistant chronic
GVHD. Blood 107: 3074-3080, 2006.
67. Couriel DR, Saliba R, de Lima M, Giralt S, Andersson B,
Khouri I, Hosing C, Ippoliti C, Shpall EJ, Champlin R, and
Alousi A. A phase III study of infliximab and corticosteroids
for the initial treatment of acute graft-versus-host disease.
Biology of blood and marrow transplantation : journal of the
American Society for Blood and Marrow Transplantation 15:
1555-1562, 2009.
68. Couriel DR, Saliba R, Escalon MP, Hsu Y, Ghosh S, Ippoliti C,
Hicks K, Donato M, Giralt S, Khouri IF, Hosing C, de Lima
MJ, Andersson B, Neumann J, and Champlin R. Sirolimus in
combination with tacrolimus and corticosteroids for the treat-
ment of resistant chronic graft-versus-host disease. British
journal of haematology 130: 409-417, 2005.
69. Couriel DR, Saliba RM, Giralt S, Khouri I, Andersson B, de
Lima M, Hosing C, Anderlini P, Donato M, Cleary K, Gajews-
ki J, Neumann J, Ippoliti C, Rondon G, Cohen A, and Cham-
plin R. Acute and chronic graft-versus-host disease after abla-
tive and nonmyeloablative conditioning for allogeneic
hematopoietic transplantation. Biology of blood and marrow
transplantation : journal of the American Society for Blood
and Marrow Transplantation 10: 178-185, 2004.
70. Cragg L, Blazar BR, Defor T, Kolatker N, Miller W, Kersey J,
Ramsay M, McGlave P, Filipovich A, and Weisdorf D. A ran-
domized trial comparing prednisone with antithymocyte glob-
ulin/prednisone as an initial systemic therapy for moderately
severe acute graft-versus-host disease. Biology of blood and
marrow transplantation : journal of the American Society for
Blood and Marrow Transplantation 6: 441-447, 2000.
71. Cuthbert RJ, Phillips GL, Barnett MJ, Nantel SH, Reece DE,
Shepherd JD, and Klingemann HG. Anti-interleukin-2 recep-
tor monoclonal antibody (BT 563) in the treatment of severe
acute GVHD refractory to systemic corticosteroid therapy.
Bone marrow transplantation 10: 451-455, 1992.
72. Cutler C, Miklos D, Kim HT, Treister N, Woo SB, Bienfang D,
Klickstein LB, Levin J, Miller K, Reynolds C, Macdonell R,
Pasek M, Lee SJ, Ho V, Soiffer R, Antin JH, Ritz J, and Alyea
E. Rituximab for steroid-refractory chronic graft-versus-host
disease. Blood 108: 756-762, 2006.
73. Cyster JG. Chemokines, sphingosine-1-phosphate, and cell
migration in secondary lymphoid organs. Annual review of
immunology 23: 127-159, 2005.
74. Chamorro-Vina C, Ruiz JR, Santana-Sosa E, Gonzalez Vicent
M, Madero L, Perez M, Fleck SJ, Perez A, Ramirez M, and
Lucia A. Exercise during hematopoietic stem cell transplant
hospitalization in children. Medicine and science in sports and
exercise 42: 1045-1053, 2010.
98 •   Graft-versus-host disease and exercise
EIR 21 2015
75. Chan EY, Lawton JW, Lie AK, and Lau CS. Autoantibody for-
mation after allogeneic bone marrow transplantation: correla-
tion with the reconstitution of CD5+ B cells and occurrence of
graft-versus-host disease. Pathology 29: 184-188, 1997.
76. Chen X, Vodanovic-Jankovic S, Johnson B, Keller M,
Komorowski R, and Drobyski WR. Absence of regulatory T-
cell control of TH1 and TH17 cells is responsible for the
autoimmune-mediated pathology in chronic graft-versus-host
disease. Blood 110: 3804-3813, 2007.
77. Chen YB, Kim HT, McDonough S, Odze RD, Yao X, Lazo-
Kallanian S, Spitzer TR, Soiffer R, Antin JH, and Ritz J. Up-
Regulation of alpha4beta7 integrin on peripheral T cell subsets
correlates with the development of acute intestinal graft-ver-
sus-host disease following allogeneic stem cell transplantation.
Biology of blood and marrow transplantation : journal of the
American Society for Blood and Marrow Transplantation 15:
1066-1076, 2009.
78. Cherel M, Choufi B, Trauet J, Cracco P, Dessaint JP, Yakoub-
Agha I, and Labalette M. Naive subset develops the most
important alloreactive response among human CD4+ T lym-
phocytes in human leukocyte antigen-identical related setting.
European journal of haematology 92: 491-496, 2014.
79. Chien JW, Martin PJ, Gooley TA, Flowers ME, Heckbert SR,
Nichols WG, and Clark JG. Airflow obstruction after mye-
loablative allogeneic hematopoietic stem cell transplantation.
American journal of respiratory and critical care medicine
168: 208-214, 2003.
80. Child FJ, Ratnavel R, Watkins P, Samson D, Apperley J, Ball J,
Taylor P, and Russell-Jones R. Extracorporeal photopheresis
(ECP) in the treatment of chronic graft-versus-host disease
(GVHD). Bone marrow transplantation 23: 881-887, 1999.
81. Choi S, and Reddy P. Graft-versus-host disease. Panminerva
medica 52: 111-124, 2010.
82. Chu YW, and Gress RE. Murine models of chronic graft-ver-
sus-host disease: insights and unresolved issues. Biology of
blood and marrow transplantation : journal of the American
Society for Blood and Marrow Transplantation 14: 365-378,
2008.
83. Dall'Amico R, and Messina C. Extracorporeal pho-
tochemotherapy for the treatment of graft-versus-host disease.
Therapeutic apheresis : official journal of the International
Society for Apheresis and the Japanese Society for Apheresis
6: 296-304, 2002.
84. Dander E, Balduzzi A, Zappa G, Lucchini G, Perseghin P,
Andre V, Todisco E, Rahal D, Migliavacca M, Longoni D,
Solinas G, Villa A, Berti E, Mina PD, Parma M, Allavena P,
Biagi E, Rovelli A, Biondi A, and D'Amico G. Interleukin-17-
producing T-helper cells as new potential player mediating
graft-versus-host disease in patients undergoing allogeneic
stem-cell transplantation. Transplantation 88: 1261-1272,
2009.
85. Darmstadt GL, Donnenberg AD, Vogelsang GB, Farmer ER,
and Horn TD. Clinical, laboratory, and histopathologic indica-
tors of the development of progressive acute graft-versus-host
disease. The Journal of investigative dermatology 99: 397-
402, 1992.
86. Das J, Ren G, Zhang L, Roberts AI, Zhao X, Bothwell AL, Van
Kaer L, Shi Y, and Das G. Transforming growth factor beta is
dispensable for the molecular orchestration of Th17 cell differ-
entiation. The Journal of experimental medicine 206: 2407-
2416, 2009.
87. de Lavallade H, Mohty M, Faucher C, Furst S, El-Cheikh J,
and Blaise D. Low-dose methotrexate as salvage therapy for
refractory graft-versus-host disease after reduced-intensity
conditioning allogeneic stem cell transplantation. Haematolog-
ica 91: 1438-1440, 2006.
88. De Wit D, Van Mechelen M, Zanin C, Doutrelepont JM, Velu
T, Gerard C, Abramowicz D, Scheerlinck JP, De Baetselier P,
Urbain J, and et al. Preferential activation of Th2 cells in
chronic graft-versus-host reaction. Journal of immunology
150: 361-366, 1993.
89. DeCook LJ, Thoma M, Huneke T, Johnson ND, Wiegand RA,
Patnaik MM, Litzow MR, Hogan WJ, Porrata LF, and Holtan
SG. Impact of lymphocyte and monocyte recovery on the out-
comes of allogeneic hematopoietic SCT with fludarabine and
melphalan conditioning. Bone Marrow Transplant 48: 708-
714, 2013.
90. Deeg HJ. How I treat refractory acute GVHD. Blood 109:
4119-4126, 2007.
91. Demirer T, Barkholt L, Blaise D, Pedrazzoli P, Aglietta M,
Carella AM, Bay JO, Arpaci F, Rosti G, Gurman G, Nieder-
wieser D, Bregni M, and Party ESTW. Transplantation of allo-
geneic hematopoietic stem cells: an emerging treatment
modality for solid tumors. Nature clinical practice Oncology 5:
256-267, 2008.
92. Dickinson AM, Middleton PG, Rocha V, Gluckman E, Holler
E, and Eurobank m. Genetic polymorphisms predicting the
outcome of bone marrow transplants. British journal of haema-
tology 127: 479-490, 2004.
93. Dighiero G, Intrator L, Cordonnier C, Tortevoye P, and Ver-
nant JP. High levels of anti-cytoskeleton autoantibodies are
frequently associated with chronic GVHD. British journal of
haematology 67: 301-305, 1987.
94. Doutrelepont JM, Moser M, Leo O, Abramowicz D, Vander-
haegen ML, Urbain J, and Goldman M. Hyper IgE in stimula-
tory graft-versus-host disease: role of interleukin-4. Clinical
and experimental immunology 83: 133-136, 1991.
95. Duffner U, Lu B, Hildebrandt GC, Teshima T, Williams DL,
Reddy P, Ordemann R, Clouthier SG, Lowler K, Liu C, Gerard
C, Cooke KR, and Ferrara JL. Role of CXCR3-induced donor
T-cell migration in acute GVHD. Experimental hematology
31: 897-902, 2003.
96. Dutt S, Ermann J, Tseng D, Liu YP, George TI, Fathman CG,
and Strober S. L-selectin and beta7 integrin on donor CD4 T
cells are required for the early migration to host mesenteric
lymph nodes and acute colitis of graft-versus-host disease.
Blood 106: 4009-4015, 2005.
97. Dutt S, Tseng D, Ermann J, George TI, Liu YP, Davis CR,
Fathman CG, and Strober S. Naive and memory T cells induce
different types of graft-versus-host disease. Journal of
immunology 179: 6547-6554, 2007.
98. Epstein JB, Gorsky M, Epstein MS, and Nantel S. Topical aza-
thioprine in the treatment of immune-mediated chronic oral
inflammatory conditions: a series of cases. Oral surgery, oral
medicine, oral pathology, oral radiology, and endodontics 91:
56-61, 2001.
99. Fang B, Song Y, Liao L, Zhang Y, and Zhao RC. Favorable
response to human adipose tissue-derived mesenchymal stem
cells in steroid-refractory acute graft-versus-host disease.
Transplantation proceedings 39: 3358-3362, 2007.
100. Fassil H, Bassim CW, Mays J, Edwards D, Baird K, Steinberg
SM, Williams KM, Cowen EW, Mitchell SA, Hakim FT, Tay-
Graft-versus-host disease and exercise •   99
EIR 21 2015
lor T, Avila D, Zhang D, Grkovic L, Datiles M, Gress RE, and
Pavletic SZ. Oral chronic graft-vs.-host disease characteriza-
tion using the NIH scale. Journal of dental research 91: 45S-
51S, 2012.
101. Fedoriw Y, Deal AM, and Dunphy CH. Decreased TdT+ Bone
Marrow B Cell Precursors after Allogeneic Stem Cell Trans-
plantation is Associated with Development of Human Chronic
Graft versus Host Disease (cGVHD). . In: B Cells: New
Insights into Normal versus Dysregulated Function edited by
Rawlings DJ, Lund FE, Tangye SG, and Monroe JG. Whistler,
British Columbia: Keystone Symposia, 2011.
102. Ferrara J, and Antin J. The pathophysiology of graft vs.-host
disease. In: Thomas’ Hematopoietic Cell Transplantation, edit-
ed by Blume KG, Forman SJ, and Appelbaum FR. Malden,
MA: Blackwell, 2004, p. 353-368.
103. Ferrara JL. Cellular and molecular mechanisms of graft-ver-
sus-host disease. Transfusion science 15: 197-206, 1994.
104. Ferrara JL, and Antin JH. The pathophysiology of graft-ver-
sus-host disease. In: Hematopoietic cell transplantation, edited
by Blume KG, and Forman SJ. Malden, MA: Blackwell Sci-
ence, 1999, p. 305-315.
105. Ferrara JL, and Deeg HJ. Graft-versus-host disease. The New
England journal of medicine 324: 667-674, 1991.
106. Ferrara JL, and Krenger W. Graft-versus-host disease: the
influence of type 1 and type 2 T cell cytokines. Transfusion
medicine reviews 12: 1-17, 1998.
107. Ferrara JL, Levine JE, Reddy P, and Holler E. Graft-versus-
host disease. Lancet 373: 1550-1561, 2009.
108. Ferrara JL, and Reddy P. Pathophysiology of graft-versus-host
disease. Seminars in hematology 43: 3-10, 2006.
109. Ferrara JLM, Cooke KR, and Teshima T. The pathophysiology
of Graft-vs.-Host Disease. . In: Graft-vs-Host Disease, edited
by Ferrara J, Cooke K, and Deeg J. New York: Marcel Dekker,
2005, p. 1-34.
110. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR,
Lee SJ, Martin P, Chien J, Przepiorka D, Couriel D, Cowen
EW, Dinndorf P, Farrell A, Hartzman R, Henslee-Downey J,
Jacobsohn D, McDonald G, Mittleman B, Rizzo JD, Robinson
M, Schubert M, Schultz K, Shulman H, Turner M, Vogelsang
G, and Flowers ME. National Institutes of Health consensus
development project on criteria for clinical trials in chronic
graft-versus-host disease: I. Diagnosis and staging working
group report. Biology of blood and marrow transplantation :
journal of the American Society for Blood and Marrow Trans-
plantation 11: 945-956, 2005.
111. Fimiani M, De Aloe G, and Cuccia A. Chronic graft versus
host disease and skin. Journal of the European Academy of
Dermatology and Venereology : JEADV 17: 512-517, 2003.
112. Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M,
Zander AR, Volin L, Ruutu T, Heim DA, Schwerdtfeger R,
Kolbe K, Mayer J, Maertens JA, Linkesch W, Holler E, Koza
V, Bornhauser M, Einsele H, Kolb HJ, Bertz H, Egger M,
Grishina O, Socie G, and Group AT-FT. Standard graft-versus-
host disease prophylaxis with or without anti-T-cell globulin in
haematopoietic cell transplantation from matched unrelated
donors: a randomised, open-label, multicentre phase 3 trial.
The lancet oncology 10: 855-864, 2009.
113. Fiuza-Luces C, Delmiro A, Soares-Miranda L, Gonzalez-
Murillo A, Martinez-Palacios J, Ramirez M, Lucia A, and
Moran M. Exercise training can induce cardiac autophagy at
end-stage chronic conditions: Insights from a graft-versus-
host-disease mouse model. Brain, behavior, and immunity 39:
56-60, 2014.
114. Fiuza-Luces C, Garatachea N, Berger NA, and Lucia A. Exer-
cise is the Real Polypill. Physiology 28: 330-358, 2013.
115. Fiuza-Luces C, Gonzalez-Murillo A, Soares-Miranda L, Pala-
cio JM, Colmenero I, Casco F, Melen G, Moran M, Lucia A,
and Ramirez M. Effects of Exercise Interventions in Graft Ver-
sus Host Disease Models. Cell transplantation 2012.
116. Fiuza-Luces C, Soares-Miranda L, Gonzalez-Murillo A, Pala-
cio JM, Colmenero I, Casco F, Melen GJ, Delmiro A, Moran
M, Ramirez M, and Lucia A. Exercise Benefits in Chronic
Graft versus Host Disease: A Murine Model Study. Medicine
and science in sports and exercise 45: 1703-1711, 2013.
117. Flowers ME, Apperley JF, van Besien K, Elmaagacli A, Grigg
A, Reddy V, Bacigalupo A, Kolb HJ, Bouzas L, Michallet M,
Prince HM, Knobler R, Parenti D, Gallo J, and Greinix HT. A
multicenter prospective phase 2 randomized study of extracor-
poreal photopheresis for treatment of chronic graft-versus-host
disease. Blood 112: 2667-2674, 2008.
118. Foss FM, DiVenuti GM, Chin K, Sprague K, Grodman H,
Klein A, Chan G, Stiffler K, and Miller KB. Prospective study
of extracorporeal photopheresis in steroid-refractory or
steroid-resistant extensive chronic graft-versus-host disease:
analysis of response and survival incorporating prognostic fac-
tors. Bone marrow transplantation 35: 1187-1193, 2005.
119. Fraser CJ, Bhatia S, Ness K, Carter A, Francisco L, Arora M,
Parker P, Forman S, Weisdorf D, Gurney JG, and Baker KS.
Impact of chronic graft-versus-host disease on the health status
of hematopoietic cell transplantation survivors: a report from
the Bone Marrow Transplant Survivor Study. Blood 108:
2867-2873, 2006.
120. Frey FJ, Ruegsegger MK, and Frey BM. The dose-dependent
systemic availability of prednisone: one reason for the reduced
biological effect of alternate-day prednisone. British journal of
clinical pharmacology 21: 183-189, 1986.
121. Fujii H, Cuvelier G, She K, Aslanian S, Shimizu H, Kariminia
A, Krailo M, Chen Z, McMaster R, Bergman A, Goldman F,
Grupp SA, Wall DA, Gilman AL, and Schultz KR. Biomarkers
in newly diagnosed pediatric-extensive chronic graft-versus-
host disease: a report from the Children's Oncology Group.
Blood 111: 3276-3285, 2008.
122. Fujii N, Takenaka K, Shinagawa K, Ikeda K, Maeda Y, Sunami
K, Hiramatsu Y, Matsuo K, Ishimaru F, Niiya K, Yoshino T,
Hirabayashi N, and Harada M. Hepatic graft-versus-host dis-
ease presenting as an acute hepatitis after allogeneic peripheral
blood stem cell transplantation. Bone marrow transplantation
27: 1007-1010, 2001.
123. Funke VA, de Medeiros CR, Setubal DC, Ruiz J, Bitencourt
MA, Bonfim CM, Neto JZ, and Pasquini R. Therapy for severe
refractory acute graft-versus-host disease with basiliximab, a
selective interleukin-2 receptor antagonist. Bone marrow
transplantation 37: 961-965, 2006.
124. Furlong T, Martin P, Flowers ME, Carnevale-Schianca F,
Yatscoff R, Chauncey T, Appelbaum FR, Deeg HJ, Doney K,
Witherspoon R, Storer B, Sullivan KM, Storb R, and Nash
RA. Therapy with mycophenolate mofetil for refractory acute
and chronic GVHD. Bone marrow transplantation 44: 739-
748, 2009.
125. Garcia-Cadenas I, Valcarcel D, Martino R, Pinana JL, Nov-
elli S, Esquirol A, Garrido A, Moreno ME, Granell M,
Moreno C, Saavedra S, Briones J, Brunet S, and Sierra J.
100 •   Graft-versus-host disease and exercise
EIR 21 2015
Updated experience with inolimomab as treatment for corti-
costeroid-refractory acute graft-versus-host disease. Biology
of blood and marrow transplantation : journal of the Ameri-
can Society for Blood and Marrow Transplantation 19: 435-
439, 2013.
126. Garlisi CG, Pennline KJ, Smith SR, Siegel MI, and Umland
SP. Cytokine gene expression in mice undergoing chronic
graft-versus-host disease. Molecular immunology 30: 669-
677, 1993.
127. Garnett C, Apperley JF, and Pavlu J. Treatment and manage-
ment of graft--host disease: improving response and survival.
Therapeutic advances in hematology 4: 366-378, 2013.
128. Gatza E, Rogers CE, Clouthier SG, Lowler KP, Tawara I, Liu
C, Reddy P, and Ferrara JL. Extracorporeal photopheresis
reverses experimental graft-versus-host disease through regu-
latory T cells. Blood 112: 1515-1521, 2008.
129. George B, Danda D, Chandy M, Srivastava A, and Mathews V.
Polymyositis--an unusual manifestation of chronic graft-ver-
sus-host disease. Rheumatology international 20: 169-170,
2001.
130. Ghoreschi K, Laurence A, Yang XP, Tato CM, McGeachy MJ,
Konkel JE, Ramos HL, Wei L, Davidson TS, Bouladoux N,
Grainger JR, Chen Q, Kanno Y, Watford WT, Sun HW, Eberl
G, Shevach EM, Belkaid Y, Cua DJ, Chen W, and O'Shea JJ.
Generation of pathogenic T(H)17 cells in the absence of TGF-
beta signalling. Nature 467: 967-971, 2010.
131. Ghoreschi K, Thomas P, Penovici M, Ullmann J, Sander CA,
Ledderose G, Plewig G, Kolb HJ, and Rocken M. PUVA-bath
photochemotherapy and isotretinoin in sclerodermatous graft-
versus-host disease. European journal of dermatology : EJD
18: 667-670, 2008.
132. Giaccone L, Martin P, Carpenter P, Moravec C, Hooper H,
Funke VA, Storb R, and Flowers ME. Safety and potential effi-
cacy of low-dose methotrexate for treatment of chronic graft-
versus-host disease. Bone marrow transplantation 36: 337-
341, 2005.
133. Gilman AL, Chan KW, Mogul A, Morris C, Goldman FD,
Boyer M, Cirenza E, Mazumder A, Gehan E, Cahill R, Frankel
S, and Schultz K. Hydroxychloroquine for the treatment of
chronic graft-versus-host disease. Biology of blood and mar-
row transplantation : journal of the American Society for
Blood and Marrow Transplantation 6: 327-334, 2000.
134. Goker H, Haznedaroglu IC, and Chao NJ. Acute graft-vs-host
disease: pathobiology and management. Experimental hema-
tology 29: 259-277, 2001.
135. Goldberg JD, Jacobsohn DA, Margolis J, Chen AR, Anders V,
Phelps M, and Vogelsang GB. Pentostatin for the treatment of
chronic graft-versus-host disease in children. Journal of pedi-
atric hematology/oncology 25: 584-588, 2003.
136. Gomez-Almaguer D, Ruiz-Arguelles GJ, del Carmen Tarin-
Arzaga L, Gonzalez-Llano O, Gutierrez-Aguirre H, Cantu-
Rodriguez O, Jaime-Perez J, Carrasco-Yalan A, and Giralt S.
Alemtuzumab for the treatment of steroid-refractory acute
graft-versus-host disease. Biology of blood and marrow trans-
plantation : journal of the American Society for Blood and
Marrow Transplantation 14: 10-15, 2008.
137. Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML,
Boeckh M, Martin PJ, Sandmaier BM, Marr KA, Appelbaum
FR, Storb R, and McDonald GB. Reduced mortality after allo-
geneic hematopoietic-cell transplantation. The New England
journal of medicine 363: 2091-2101, 2010.
138. Gorgun G, Miller KB, and Foss FM. Immunologic mecha-
nisms of extracorporeal photochemotherapy in chronic graft-
versus-host disease. Blood 100: 941-947, 2002.
139. Goulmy E, Schipper R, Pool J, Blokland E, Falkenburg JH,
Vossen J, Gratwohl A, Vogelsang GB, van Houwelingen HC,
and van Rood JJ. Mismatches of minor histocompatibility
antigens between HLA-identical donors and recipients and the
development of graft-versus-host disease after bone marrow
transplantation. The New England journal of medicine 334:
281-285, 1996.
140. Gratwohl A, Baldomero H, Aljurf M, Pasquini MC, Bouzas
LF, Yoshimi A, Szer J, Lipton J, Schwendener A, Gratwohl M,
Frauendorfer K, Niederwieser D, Horowitz M, Kodera Y,
Worldwide Network of B, and Marrow T. Hematopoietic stem
cell transplantation: a global perspective. JAMA : the journal
of the American Medical Association 303: 1617-1624, 2010.
141. Grauer O, Wolff D, Bertz H, Greinix H, Kuhl JS, Lawitschka
A, Lee SJ, Pavletic SZ, Holler E, and Kleiter I. Neurological
manifestations of chronic graft-versus-host disease after allo-
geneic haematopoietic stem cell transplantation: report from
the Consensus Conference on Clinical Practice in chronic
graft-versus-host disease. Brain : a journal of neurology 133:
2852-2865, 2010.
142. Graze PR, and Gale RP. Chronic graft versus host disease: a
syndrome of disordered immunity. The American journal of
medicine 66: 611-620, 1979.
143. Greenspan A, Deeg HJ, Cottler-Fox M, Sirdofski M, Spitzer
TR, and Kattah J. Incapacitating peripheral neuropathy as a
manifestation of chronic graft-versus-host disease. Bone mar-
row transplantation 5: 349-352, 1990.
144. Greinix HT, Knobler RM, Worel N, Schneider B, Schneeberger
A, Hoecker P, Mitterbauer M, Rabitsch W, Schulenburg A, and
Kalhs P. The effect of intensified extracorporeal photochemother-
apy on long-term survival in patients with severe acute graft-ver-
sus-host disease. Haematologica 91: 405-408, 2006.
145. Greinix HT, Socie G, Bacigalupo A, Holler E, Edinger MG,
Apperley JF, Schwarz T, Ullrich SE, Albert ML, Knobler RM,
Peritt D, and Ferrara JL. Assessing the potential role of photo-
pheresis in hematopoietic stem cell transplant. Bone marrow
transplantation 38: 265-273, 2006.
146. Greinix HT, Volc-Platzer B, Kalhs P, Fischer G, Rosenmayr A,
Keil F, Honigsmann H, and Knobler RM. Extracorporeal pho-
tochemotherapy in the treatment of severe steroid-refractory
acute graft-versus-host disease: a pilot study. Blood 96: 2426-
2431, 2000.
147. Greinix HT, Volc-Platzer B, Rabitsch W, Gmeinhart B, Gue-
vara-Pineda C, Kalhs P, Krutmann J, Honigsmann H, Ciovica
M, and Knobler RM. Successful use of extracorporeal pho-
tochemotherapy in the treatment of severe acute and chronic
graft-versus-host disease. Blood 92: 3098-3104, 1998.
148. Gyurkocza B, Rezvani A, and Storb RF. Allogeneic
hematopoietic cell transplantation: the state of the art. Expert
review of hematology 3: 285-299, 2010.
149. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy
TL, Murphy KM, and Weaver CT. Interleukin 17-producing
CD4+ effector T cells develop via a lineage distinct from the T
helper type 1 and 2 lineages. Nature immunology 6: 1123-
1132, 2005.
150. Harris AC, Ferrara JL, and Levine JE. Advances in predicting
acute GVHD. British journal of haematology 160: 288-302,
2013.
Graft-versus-host disease and exercise •   101
EIR 21 2015
151. Herrera AF, Kim HT, Bindra B, Jones KT, Alyea EP, 3rd,
Armand P, Cutler CS, Ho VT, Nikiforow S, Blazar BR, Ritz J,
Antin JH, Soiffer RJ, and Koreth J. A Phase II Study of Borte-
zomib Plus Prednisone for Initial Therapy of Chronic Graft-
versus-Host Disease. Biology of blood and marrow transplan-
tation : journal of the American Society for Blood and Marrow
Transplantation 2014.
152. Herrmann R, Sturm M, Shaw K, Purtill D, Cooney J, Wright
M, Phillips M, and Cannell P. Mesenchymal stromal cell thera-
py for steroid-refractory acute and chronic graft versus host
disease: a phase 1 study. International journal of hematology
95: 182-188, 2012.
153. Higman MA, and Vogelsang GB. Chronic graft versus host
disease. British journal of haematology 125: 435-454, 2004.
154. Hildebrandt GC, Fazekas T, Lawitschka A, Bertz H, Greinix
H, Halter J, Pavletic SZ, Holler E, and Wolff D. Diagnosis and
treatment of pulmonary chronic GVHD: report from the con-
sensus conference on clinical practice in chronic GVHD. Bone
marrow transplantation 46: 1283-1295, 2011.
155. Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, and
Ferrara JL. Total body irradiation and acute graft-versus-host
disease: the role of gastrointestinal damage and inflammatory
cytokines. Blood 90: 3204-3213, 1997.
156. Hill GR, and Ferrara JL. The primacy of the gastrointestinal
tract as a target organ of acute graft-versus-host disease:
rationale for the use of cytokine shields in allogeneic bone
marrow transplantation. Blood 95: 2754-2759, 2000.
157. Hillebrandt S, Wasmuth HE, Weiskirchen R, Hellerbrand C,
Keppeler H, Werth A, Schirin-Sokhan R, Wilkens G, Geier A,
Lorenzen J, Kohl J, Gressner AM, Matern S, and Lammert F.
Complement factor 5 is a quantitative trait gene that modifies
liver fibrogenesis in mice and humans. Nature genetics 37:
835-843, 2005.
158. Hings IM, Filipovich AH, Miller WJ, Blazar BL, McGlave PB,
Ramsay NK, Kersey JH, and Weisdorf DJ. Prednisone therapy
for acute graft-versus-host disease: short- versus long-term
treatment. A prospective randomized trial. Transplantation 56:
577-580, 1993.
159. Hjermstad M, Holte H, Evensen S, Fayers P, and Kaasa S. Do
patients who are treated with stem cell transplantation have a
health-related quality of life comparable to the general popula-
tion after 1 year? Bone Marrow Transplant 24: 911-918, 1999.
160. Ho VT, and Soiffer RJ. The history and future of T-cell deple-
tion as graft-versus-host disease prophylaxis for allogeneic
hematopoietic stem cell transplantation. Blood 98: 3192-3204,
2001.
161. Ho VT, Zahrieh D, Hochberg E, Micale E, Levin J, Reynolds
C, Steckel S, Cutler C, Fisher DC, Lee SJ, Alyea EP, Ritz J,
Soiffer RJ, and Antin JH. Safety and efficacy of denileukin
diftitox in patients with steroid-refractory acute graft-versus-
host disease after allogeneic hematopoietic stem cell trans-
plantation. Blood 104: 1224-1226, 2004.
162. Hockenbery DM, Cruickshank S, Rodell TC, Gooley T,
Schuening F, Rowley S, David D, Brunvand M, Berryman B,
Abhyankar S, Bouvier M, and McDonald GB. A randomized,
placebo-controlled trial of oral beclomethasone dipropionate
as a prednisone-sparing therapy for gastrointestinal graft-ver-
sus-host disease. Blood 109: 4557-4563, 2007.
163. Hoda D, Pidala J, Salgado-Vila N, Kim J, Perkins J, Bookout
R, Field T, Perez L, Ayala E, Ochoa-Bayona JL, Raychaudhuri
J, Alsina M, Greene J, Janssen W, Fernandez HF, Anasetti C,
and Kharfan-Dabaja MA. Sirolimus for treatment of steroid-
refractory acute graft-versus-host disease. Bone marrow trans-
plantation 45: 1347-1351, 2010.
164. Hsieh CS, Heimberger AB, Gold JS, O'Garra A, and Murphy
KM. Differential regulation of T helper phenotype develop-
ment by interleukins 4 and 10 in an alpha beta T-cell-receptor
transgenic system. Proceedings of the National Academy of
Sciences of the United States of America 89: 6065-6069, 1992.
165. Hsieh CS, Macatonia SE, Tripp CS, Wolf SF, O'Garra A, and
Murphy KM. Development of TH1 CD4+ T cells through IL-
12 produced by Listeria-induced macrophages. Science 260:
547-549, 1993.
166. Huang XJ, Jiang Q, Chen H, Xu L, Liu D, Chen Y, Han W,
Zhang Y, Liu K, and Lu D. Low-dose methotrexate for the
treatment of graft-versus-host disease after allogeneic
hematopoietic stem cell transplantation. Bone marrow trans-
plantation 36: 343-348, 2005.
167. Imanguli MM, Swaim WD, League SC, Gress RE, Pavletic
SZ, and Hakim FT. Increased T-bet+ cytotoxic effectors and
type I interferon-mediated processes in chronic graft-versus-
host disease of the oral mucosa. Blood 113: 3620-3630, 2009.
168. Inagaki J, Nagatoshi Y, Hatano M, Isomura N, Sakiyama M,
and Okamura J. Low-dose MTX for the treatment of acute and
chronic graft-versus-host disease in children. Bone marrow
transplantation 41: 571-577, 2008.
169. Inamoto Y, Martin PJ, Storer BE, Palmer J, Weisdorf D, Pidala
J, Flowers ME, Arora M, Jagasia M, Arai S, Chai X, Pavletic
SZ, Vogelsang GB, and Lee SJ. Association of organ severity
with mortality and recurrent malignancy in chronic graft-ver-
sus-host disease. Haematologica 2014.
170. Inoue J, Ono R, Okamura A, Matsui T, Takekoshi H, Miwa M,
Kurosaka M, Saura R, and Shimada T. The impact of early
rehabilitation on the duration of hospitalization in patients
after allogeneic hematopoietic stem cell transplantation. Trans-
plantation proceedings 42: 2740-2744, 2010.
171. Iwasaki A, and Medzhitov R. Toll-like receptor control of the
adaptive immune responses. Nature immunology 5: 987-995,
2004.
172. Jacobi AM, Odendahl M, Reiter K, Bruns A, Burmester GR,
Radbruch A, Valet G, Lipsky PE, and Dorner T. Correlation
between circulating CD27high plasma cells and disease activi-
ty in patients with systemic lupus erythematosus. Arthritis and
rheumatism 48: 1332-1342, 2003.
173. Jacobsohn DA, Chen AR, Zahurak M, Piantadosi S, Anders V,
Bolanos-Meade J, Higman M, Margolis J, Kaup M, and Vogel-
sang GB. Phase II study of pentostatin in patients with corti-
costeroid-refractory chronic graft-versus-host disease. Journal
of clinical oncology : official journal of the American Society
of Clinical Oncology 25: 4255-4261, 2007.
174. Jacobsohn DA, Gilman AL, Rademaker A, Browning B, Grim-
ley M, Lehmann L, Nemecek ER, Thormann K, Schultz KR,
and Vogelsang GB. Evaluation of pentostatin in corticosteroid-
refractory chronic graft-versus-host disease in children: a
Pediatric Blood and Marrow Transplant Consortium study.
Blood 114: 4354-4360, 2009.
175. Jaffee BD, and Claman HN. Chronic graft-versus-host disease
(GVHD) as a model for scleroderma. I. Description of model
systems. Cellular immunology 77: 1-12, 1983.
176. Jagasia M, Arora M, Flowers ME, Chao NJ, McCarthy PL,
Cutler CS, Urbano-Ispizua A, Pavletic SZ, Haagenson MD,
Zhang MJ, Antin JH, Bolwell BJ, Bredeson C, Cahn JY, Cairo
102 •   Graft-versus-host disease and exercise
EIR 21 2015
M, Gale RP, Gupta V, Lee SJ, Litzow M, Weisdorf DJ,
Horowitz MM, and Hahn T. Risk factors for acute GVHD and
survival after hematopoietic cell transplantation. Blood 119:
296-307, 2012.
177. Jarden M, Baadsgaard MT, Hovgaard DJ, Boesen E, and
Adamsen L. A randomized trial on the effect of a multimodal
intervention on physical capacity, functional performance and
quality of life in adult patients undergoing allogeneic SCT.
Bone marrow transplantation 43: 725-737, 2009.
178. Jedlickova Z, Burlakova I, Bug G, Baurmann H, Schwerdt-
feger R, and Schleuning M. Therapy of sclerodermatous
chronic graft-versus-host disease with mammalian target of
rapamycin inhibitors. Biology of blood and marrow transplan-
tation : journal of the American Society for Blood and Marrow
Transplantation 17: 657-663, 2011.
179. Johnston A, Gudjonsson JE, Sigmundsdottir H, Ludviksson
BR, and Valdimarsson H. The anti-inflammatory action of
methotrexate is not mediated by lymphocyte apoptosis, but by
the suppression of activation and adhesion molecules. Clinical
immunology 114: 154-163, 2005.
180. Johnston LJ, Brown J, Shizuru JA, Stockerl-Goldstein KE,
Stuart MJ, Blume KG, Negrin RS, and Chao NJ. Rapamycin
(sirolimus) for treatment of chronic graft-versus-host disease.
Biology of blood and marrow transplantation : journal of the
American Society for Blood and Marrow Transplantation 11:
47-55, 2005.
181. Jurado M, Vallejo C, Perez-Simon JA, Brunet S, Ferra C, Bal-
salobre P, Perez-Oteyza J, Espigado I, Romero A, Caballero D,
Sierra J, Ribera JM, and Diez JL. Sirolimus as part of
immunosuppressive therapy for refractory chronic graft-ver-
sus-host disease. Biology of blood and marrow transplantation
: journal of the American Society for Blood and Marrow
Transplantation 13: 701-706, 2007.
182. Kagi D, Vignaux F, Ledermann B, Burki K, Depraetere V,
Nagata S, Hengartner H, and Golstein P. Fas and perforin path-
ways as major mechanisms of T cell-mediated cytotoxicity.
Science 265: 528-530, 1994.
183. Kanold J, Merlin E, Halle P, Paillard C, Marabelle A, Rapatel
C, Evrard B, Berger C, Stephan JL, Galambrun C, Piguet C,
D'Incan M, Bordigoni P, and Demeocq F. Photopheresis in
pediatric graft-versus-host disease after allogeneic marrow
transplantation: clinical practice guidelines based on field
experience and review of the literature. Transfusion 47: 2276-
2289, 2007.
184. Kanold J, Messina C, Halle P, Locatelli F, Lanino E, Cesaro S,
Demeocq F, Paediatric Diseases Working Party of the Euro-
pean Group for B, and Marrow T. Update on extracorporeal
photochemotherapy for graft-versus-host disease treatment.
Bone marrow transplantation 35 Suppl 1: S69-71, 2005.
185. Kappel LW, Goldberg GL, King CG, Suh DY, Smith OM, Ligh
C, Holland AM, Grubin J, Mark NM, Liu C, Iwakura Y, Heller
G, and van den Brink MR. IL-17 contributes to CD4-mediated
graft-versus-host disease. Blood 113: 945-952, 2009.
186. Kapur R, Ebeling S, and Hagenbeek A. B-cell involvement in
chronic graft-versus-host disease. Haematologica 93: 1702-
1711, 2008.
187. Kebriaei P, Isola L, Bahceci E, Holland K, Rowley S,
McGuirk J, Devetten M, Jansen J, Herzig R, Schuster M,
Monroy R, and Uberti J. Adult human mesenchymal stem cells
added to corticosteroid therapy for the treatment of acute graft-
versus-host disease. Biology of blood and marrow transplanta-
tion : journal of the American Society for Blood and Marrow
Transplantation 15: 804-811, 2009.
188. Kennedy GA, Butler J, Western R, Morton J, Durrant S, and
Hill GR. Combination antithymocyte globulin and soluble
TNFalpha inhibitor (etanercept) +/- mycophenolate mofetil for
treatment of steroid refractory acute graft-versus-host disease.
Bone marrow transplantation 37: 1143-1147, 2006.
189. Kharfan-Dabaja MA, and Cutler CS. Rituximab for prevention
and treatment of graft-versus-host disease. International jour-
nal of hematology 93: 578-585, 2011.
190. Kharfan-Dabaja MA, Mhaskar AR, Djulbegovic B, Cutler C,
Mohty M, and Kumar A. Efficacy of rituximab in the setting of
steroid-refractory chronic graft-versus-host disease: a system-
atic review and meta-analysis. Biology of blood and marrow
transplantation : journal of the American Society for Blood
and Marrow Transplantation 15: 1005-1013, 2009.
191. Khoury H, Kashyap A, Adkins DR, Brown RA, Miller G, Vij
R, Westervelt P, Trinkaus K, Goodnough LT, Hayashi RJ,
Parker P, Forman SJ, and DiPersio JF. Treatment of steroid-
resistant acute graft-versus-host disease with anti-thymocyte
globulin. Bone marrow transplantation 27: 1059-1064, 2001.
192. Kier P, Penner E, Bakos S, Kalhs P, Lechner K, Volc-Platzer B,
Wesierska-Gadek J, Sauermann G, Gadner H, Emminger-
Schmidmeier W, and et al. Autoantibodies in chronic GVHD:
high prevalence of antinucleolar antibodies. Bone marrow
transplantation 6: 93-96, 1990.
193. Kim JG, Sohn SK, Kim DH, Lee NY, Suh JS, Lee KS, and Lee
KB. Different efficacy of mycophenolate mofetil as salvage
treatment for acute and chronic GVHD after allogeneic stem
cell transplant. European journal of haematology 73: 56-61,
2004.
194. Kim SD, and Kim HS. A series of bed exercises to improve
lymphocyte count in allogeneic bone marrow transplantation
patients. European journal of cancer care 15: 453-457, 2006.
195. Kim SJ, Lee JW, Jung CW, Min CK, Cho B, Shin HJ, Chung
JS, Kim H, Lee WS, Joo YD, Yang DH, Kook H, Kang HJ,
Ahn HS, Yoon SS, Sohn SK, Min YH, Min WS, Park HS, and
Won JH. Weekly rituximab followed by monthly rituximab
treatment for steroid-refractory chronic graft-versus-host dis-
ease: results from a prospective, multicenter, phase II study.
Haematologica 95: 1935-1942, 2010.
196. Kiss TL, Abdolell M, Jamal N, Minden MD, Lipton JH, and
Messner HA. Long-term medical outcomes and quality-of-life
assessment of patients with chronic myeloid leukemia fol-
lowed at least 10 years after allogeneic bone marrow trans-
plantation. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 20: 2334-2343, 2002.
197. Koc S, Leisenring W, Flowers ME, Anasetti C, Deeg HJ, Nash
RA, Sanders JE, Witherspoon RP, Appelbaum FR, Storb R,
and Martin PJ. Thalidomide for treatment of patients with
chronic graft-versus-host disease. Blood 96: 3995-3996, 2000.
198. Koc S, Leisenring W, Flowers ME, Anasetti C, Deeg HJ, Nash
RA, Sanders JE, Witherspoon RP, Storb R, Appelbaum FR,
and Martin PJ. Therapy for chronic graft-versus-host disease: a
randomized trial comparing cyclosporine plus prednisone ver-
sus prednisone alone. Blood 100: 48-51, 2002.
199. Kolb HJ. Graft-versus-leukemia effects of transplantation and
donor lymphocytes. Blood 112: 4371-4383, 2008.
200. Kopp M, Schweigkofler H, Holzner B, Nachbaur D, Nieder-
wieser D, Fleischhacker WW, and Sperner-Unterweger B.
Time after bone marrow transplantation as an important vari-
Graft-versus-host disease and exercise •   103
EIR 21 2015
able for quality of life: results of a cross-sectional investiga-
tion using two different instruments for quality-of-life assess-
ment. Annals of hematology 77: 27-32, 1998.
201. Korn T, Bettelli E, Oukka M, and Kuchroo VK. IL-17 and
Th17 Cells. Annual review of immunology 27: 485-517, 2009.
202. Korngold R, and Sprent J. Features of T cells causing H-2-
restricted lethal graft-vs.-host disease across minor histocom-
patibility barriers. The Journal of experimental medicine 155:
872-883, 1982.
203. Korngold R, and Sprent J. Lethal graft-versus-host disease
after bone marrow transplantation across minor histocompati-
bility barriers in mice. Prevention by removing mature T cells
from marrow. The Journal of experimental medicine 148:
1687-1698, 1978.
204. Kraus PD, Wolff D, Grauer O, Angstwurm K, Jarius S,
Wandinger KP, Holler E, Schulte-Mattler W, and Kleiter I.
Muscle cramps and neuropathies in patients with allogeneic
hematopoietic stem cell transplantation and graft-versus-host
disease. PloS one 7: e44922, 2012.
205. Krejci M, Doubek M, Buchler T, Brychtova Y, Vorlicek J, and
Mayer J. Mycophenolate mofetil for the treatment of acute and
chronic steroid-refractory graft-versus-host disease. Annals of
hematology 84: 681-685, 2005.
206. Krenger W, Falzarano G, Delmonte J, Jr., Snyder KM, Byon
JC, and Ferrara JL. Interferon-gamma suppresses T-cell prolif-
eration to mitogen via the nitric oxide pathway during experi-
mental acute graft-versus-host disease. Blood 88: 1113-1121,
1996.
207. Krenger W, and Hollander GA. The immunopathology of thymic
GVHD. Seminars in immunopathology 30: 439-456, 2008.
208. Krenger W, Snyder KM, Byon JC, Falzarano G, and Ferrara
JL. Polarized type 2 alloreactive CD4+ and CD8+ donor T
cells fail to induce experimental acute graft-versus-host dis-
ease. Journal of immunology 155: 585-593, 1995.
209. Kulkarni S, Powles R, Sirohi B, Treleaven J, Saso R, Horton
C, Atra A, Ortin M, Rudin C, Goyal S, Sankpal S, Meller S,
Pinkerton CR, Mehta J, and Singhal S. Thalidomide after allo-
geneic haematopoietic stem cell transplantation: activity in
chronic but not in acute graft-versus-host disease. Bone mar-
row transplantation 32: 165-170, 2003.
210. Kuzmina Z, Greinix HT, Weigl R, Kormoczi U, Rottal A,
Frantal S, Eder S, and Pickl WF. Significant differences in B-
cell subpopulations characterize patients with chronic graft-
versus-host disease-associated dysgammaglobulinemia. Blood
117: 2265-2274, 2011.
211. Kwon B. Intervention with costimulatory pathways as a thera-
peutic approach for graft-versus-host disease. Experimental &
molecular medicine 42: 675-683, 2010.
212. Lake JR, David KM, Steffen BJ, Chu AH, Gordon RD, and
Wiesner RH. Addition of MMF to dual immunosuppression
does not increase the risk of malignant short-term death after
liver transplantation. American journal of transplantation : offi-
cial journal of the American Society of Transplantation and the
American Society of Transplant Surgeons 5: 2961-2967, 2005.
213. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis
I, Lanino E, Sundberg B, Bernardo ME, Remberger M, Dini G,
Egeler RM, Bacigalupo A, Fibbe W, Ringden O, Developmen-
tal Committee of the European Group for B, and Marrow T.
Mesenchymal stem cells for treatment of steroid-resistant,
severe, acute graft-versus-host disease: a phase II study.
Lancet 371: 1579-1586, 2008.
214. Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Has-
san M, Uzunel M, and Ringden O. Treatment of severe acute
graft-versus-host disease with third party haploidentical mes-
enchymal stem cells. Lancet 363: 1439-1441, 2004.
215. Le Gros G, Ben-Sasson SZ, Seder R, Finkelman FD, and Paul
WE. Generation of interleukin 4 (IL-4)-producing cells in vivo
and in vitro: IL-2 and IL-4 are required for in vitro generation
of IL-4-producing cells. The Journal of experimental medicine
172: 921-929, 1990.
216. Lee IM, Shiroma EJ, Lobelo F, Puska P, Blair SN, Katzmarzyk
PT, and Lancet Physical Activity Series Working G. Effect of
physical inactivity on major non-communicable diseases
worldwide: an analysis of burden of disease and life expectan-
cy. Lancet 380: 219-229, 2012.
217. Lee SJ, Joffe S, Kim HT, Socie G, Gilman AL, Wingard JR,
Horowitz MM, Cella D, and Syrjala KL. Physicians' attitudes
about quality-of-life issues in hematopoietic stem cell trans-
plantation. Blood 104: 2194-2200, 2004.
218. Lee SJ, Kim HT, Ho VT, Cutler C, Alyea EP, Soiffer RJ, and
Antin JH. Quality of life associated with acute and chronic
graft-versus-host disease. Bone marrow transplantation 38:
305-310, 2006.
219. Lee SJ, Vogelsang G, and Flowers ME. Chronic graft-versus-
host disease. Biology of blood and marrow transplantation :
journal of the American Society for Blood and Marrow Trans-
plantation 9: 215-233, 2003.
220. Lee SJ, Vogelsang G, Gilman A, Weisdorf DJ, Pavletic S,
Antin JH, Horowitz MM, Akpek G, Flowers ME, Couriel D,
and Martin PJ. A survey of diagnosis, management, and grad-
ing of chronic GVHD. Biology of blood and marrow trans-
plantation : journal of the American Society for Blood and
Marrow Transplantation 8: 32-39, 2002.
221. Lee SJ, Wegner SA, McGarigle CJ, Bierer BE, and Antin JH.
Treatment of chronic graft-versus-host disease with clofaz-
imine. Blood 89: 2298-2302, 1997.
222. Lee SJ, Zahrieh D, Agura E, MacMillan ML, Maziarz RT,
McCarthy PL, Jr., Ho VT, Cutler C, Alyea EP, Antin JH, and
Soiffer RJ. Effect of up-front daclizumab when combined with
steroids for the treatment of acute graft-versus-host disease:
results of a randomized trial. Blood 104: 1559-1564, 2004.
223. Lee YK, Turner H, Maynard CL, Oliver JR, Chen D, Elson
CO, and Weaver CT. Late developmental plasticity in the T
helper 17 lineage. Immunity 30: 92-107, 2009.
224. Levine JE, Paczesny S, Mineishi S, Braun T, Choi SW,
Hutchinson RJ, Jones D, Khaled Y, Kitko CL, Bickley D, Kri-
janovski O, Reddy P, Yanik G, and Ferrara JL. Etanercept plus
methylprednisolone as initial therapy for acute graft-versus-
host disease. Blood 111: 2470-2475, 2008.
225. Levine JE, Paczesny S, and Sarantopoulos S. Clinical applica-
tions for biomarkers of acute and chronic graft-versus-host
disease. Biology of blood and marrow transplantation : journal
of the American Society for Blood and Marrow Transplanta-
tion 18: S116-124, 2012.
226. Li XC, Rothstein DM, and Sayegh MH. Costimulatory path-
ways in transplantation: challenges and new developments.
Immunological reviews 229: 271-293, 2009.
227. Liem LM, Fibbe WE, van Houwelingen HC, and Goulmy E.
Serum transforming growth factor-beta1 levels in bone mar-
row transplant recipients correlate with blood cell counts and
chronic graft-versus-host disease. Transplantation 67: 59-65,
1999.
104 •   Graft-versus-host disease and exercise
EIR 21 2015
228. Lighvani AA, Frucht DM, Jankovic D, Yamane H, Aliberti J,
Hissong BD, Nguyen BV, Gadina M, Sher A, Paul WE, and
O'Shea JJ. T-bet is rapidly induced by interferon-gamma in
lymphoid and myeloid cells. Proceedings of the National
Academy of Sciences of the United States of America 98:
15137-15142, 2001.
229. Ljungman P, Bregni M, Brune M, Cornelissen J, de Witte T,
Dini G, Einsele H, Gaspar HB, Gratwohl A, Passweg J, Peters
C, Rocha V, Saccardi R, Schouten H, Sureda A, Tichelli A,
Velardi A, Niederwieser D, European Group for B, and Mar-
row T. Allogeneic and autologous transplantation for haemato-
logical diseases, solid tumours and immune disorders: current
practice in Europe 2009. Bone marrow transplantation 45:
219-234, 2010.
230. Lohr J, Knoechel B, Wang JJ, Villarino AV, and Abbas AK.
Role of IL-17 and regulatory T lymphocytes in a systemic
autoimmune disease. The Journal of experimental medicine
203: 2785-2791, 2006.
231. Lopez F, Parker P, Nademanee A, Rodriguez R, Al-Kadhimi Z,
Bhatia R, Cohen S, Falk P, Fung H, Kirschbaum M, Krishnan
A, Kogut N, Molina A, Nakamura R, O'Donnell M, Pop-
plewell L, Pullarkat V, Rosenthal J, Sahebi F, Smith E, Snyder
D, Somlo G, Spielberger R, Stein A, Sweetman R, Zain J, and
Forman S. Efficacy of mycophenolate mofetil in the treatment
of chronic graft-versus-host disease. Biology of blood and
marrow transplantation : journal of the American Society for
Blood and Marrow Transplantation 11: 307-313, 2005.
232. Lucia A, Earnest C, and Perez M. Cancer-related fatigue: can
exercise physiology assist oncologists? The lancet oncology 4:
616-625, 2003.
233. Macmillan ML, Couriel D, Weisdorf DJ, Schwab G, Havrilla
N, Fleming TR, Huang S, Roskos L, Slavin S, Shadduck RK,
Dipersio J, Territo M, Pavletic S, Linker C, Heslop HE, Deeg
HJ, and Blazar BR. A phase 2/3 multicenter randomized clini-
cal trial of ABX-CBL versus ATG as secondary therapy for
steroid-resistant acute graft-versus-host disease. Blood 109:
2657-2662, 2007.
234. MacMillan ML, Weisdorf DJ, Brunstein CG, Cao Q, DeFor
TE, Verneris MR, Blazar BR, and Wagner JE. Acute graft-ver-
sus-host disease after unrelated donor umbilical cord blood
transplantation: analysis of risk factors. Blood 113: 2410-
2415, 2009.
235. MacMillan ML, Weisdorf DJ, Davies SM, DeFor TE, Burns
LJ, Ramsay NK, Wagner JE, and Blazar BR. Early antithymo-
cyte globulin therapy improves survival in patients with
steroid-resistant acute graft-versus-host disease. Biology of
blood and marrow transplantation : journal of the American
Society for Blood and Marrow Transplantation 8: 40-46, 2002.
236. MacMillan ML, Weisdorf DJ, Wagner JE, DeFor TE, Burns
LJ, Ramsay NK, Davies SM, and Blazar BR. Response of 443
patients to steroids as primary therapy for acute graft-versus-
host disease: comparison of grading systems. Biology of blood
and marrow transplantation : journal of the American Society
for Blood and Marrow Transplantation 8: 387-394, 2002.
237. Maeda Y. Pathogenesis of graft-versus-host disease: innate
immunity amplifying acute alloimmune responses. Interna-
tional journal of hematology 98: 293-299, 2013.
238. Magro L, Catteau B, Coiteux V, Bruno B, Jouet JP, and Yak-
oub-Agha I. Efficacy of imatinib mesylate in the treatment of
refractory sclerodermatous chronic GVHD. Bone marrow
transplantation 42: 757-760, 2008.
239. Magro L, Mohty M, Catteau B, Coiteux V, Chevallier P, Ter-
riou L, Jouet JP, and Yakoub-Agha I. Imatinib mesylate as sal-
vage therapy for refractory sclerotic chronic graft-versus-host
disease. Blood 114: 719-722, 2009.
240. Mangan PR, Harrington LE, O'Quinn DB, Helms WS, Bullard
DC, Elson CO, Hatton RD, Wahl SM, Schoeb TR, and Weaver
CT. Transforming growth factor-beta induces development of
the T(H)17 lineage. Nature 441: 231-234, 2006.
241. Mapara MY, Leng C, Kim YM, Bronson R, Lokshin A, Luster
A, and Sykes M. Expression of chemokines in GVHD target
organs is influenced by conditioning and genetic factors and
amplified by GVHR. Biology of blood and marrow transplan-
tation : journal of the American Society for Blood and Marrow
Transplantation 12: 623-634, 2006.
242. Marcellus DC, Altomonte VL, Farmer ER, Horn TD, Freemer
CS, Grant J, and Vogelsang GB. Etretinate therapy for refrac-
tory sclerodermatous chronic graft-versus-host disease. Blood
93: 66-70, 1999.
243. Martin PJ, Inamoto Y, Flowers ME, and Carpenter PA. Sec-
ondary treatment of acute graft-versus-host disease: a critical
review. Biology of blood and marrow transplantation : journal
of the American Society for Blood and Marrow Transplanta-
tion 18: 982-988, 2012.
244. Martin PJ, Rizzo JD, Wingard JR, Ballen K, Curtin PT, Cutler
C, Litzow MR, Nieto Y, Savani BN, Schriber JR, Shaughnessy
PJ, Wall DA, and Carpenter PA. First- and second-line sys-
temic treatment of acute graft-versus-host disease: recommen-
dations of the American Society of Blood and Marrow Trans-
plantation. Biology of blood and marrow transplantation :
journal of the American Society for Blood and Marrow Trans-
plantation 18: 1150-1163, 2012.
245. Martin PJ, Schoch G, Fisher L, Byers V, Anasetti C, Appel-
baum FR, Beatty PG, Doney K, McDonald GB, Sanders JE,
and et al. A retrospective analysis of therapy for acute graft-
versus-host disease: initial treatment. Blood 76: 1464-1472,
1990.
246. Martin PJ, Schoch G, Fisher L, Byers V, Appelbaum FR,
McDonald GB, Storb R, and Hansen JA. A retrospective
analysis of therapy for acute graft-versus-host disease: second-
ary treatment. Blood 77: 1821-1828, 1991.
247. Martin PJ, Storer BE, Rowley SD, Flowers ME, Lee SJ, Car-
penter PA, Wingard JR, Shaughnessy PJ, DeVetten MP, Jaga-
sia M, Fay JW, van Besien K, Gupta V, Kitko C, Johnston LJ,
Maziarz RT, Arora M, Jacobson PA, and Weisdorf D. Evalua-
tion of mycophenolate mofetil for initial treatment of chronic
graft-versus-host disease. Blood 113: 5074-5082, 2009.
248. Martin PJ, Weisdorf D, Przepiorka D, Hirschfeld S, Farrell A,
Rizzo JD, Foley R, Socie G, Carter S, Couriel D, Schultz KR,
Flowers ME, Filipovich AH, Saliba R, Vogelsang GB, Pavletic
SZ, Lee SJ, and Design of Clinical Trials Working G. National
Institutes of Health Consensus Development Project on Crite-
ria for Clinical Trials in Chronic Graft-versus-Host Disease:
VI. Design of Clinical Trials Working Group report. Biology
of blood and marrow transplantation : journal of the American
Society for Blood and Marrow Transplantation 12: 491-505,
2006.
249. Martin SJ, Audrain MA, Oksman F, Ecoiffier M, Attal M,
Milpied N, and Esnault VL. Antineutrophil cytoplasmic anti-
bodies (ANCA) in chronic graft-versus-host disease after allo-
geneic bone marrow transplantation. Bone marrow transplan-
tation 20: 45-48, 1997.
Graft-versus-host disease and exercise •   105
EIR 21 2015
250. Martinez C, Solano C, Ferra C, Sampol A, Valcarcel D, Perez-
Simon JA, and Spanish Group for Stem Cell T. Alemtuzumab
as treatment of steroid-refractory acute graft-versus-host dis-
ease: results of a phase II study. Biology of blood and marrow
transplantation : journal of the American Society for Blood
and Marrow Transplantation 15: 639-642, 2009.
251. Massenkeil G, Rackwitz S, Genvresse I, Rosen O, Dorken B,
and Arnold R. Basiliximab is well tolerated and effective in the
treatment of steroid-refractory acute graft-versus-host disease
after allogeneic stem cell transplantation. Bone marrow trans-
plantation 30: 899-903, 2002.
252. Matsuoka K, Kim HT, McDonough S, Bascug G, Warshauer
B, Koreth J, Cutler C, Ho VT, Alyea EP, Antin JH, Soiffer RJ,
and Ritz J. Altered regulatory T cell homeostasis in patients
with CD4+ lymphopenia following allogeneic hematopoietic
stem cell transplantation. The Journal of clinical investigation
120: 1479-1493, 2010.
253. Mayer J, Krejci M, Doubek M, Pospisil Z, Brychtova Y,
Tomiska M, and Racil Z. Pulse cyclophosphamide for corti-
costeroid-refractory graft-versus-host disease. Bone marrow
transplantation 35: 699-705, 2005.
254. McCormick LL, Zhang Y, Tootell E, and Gilliam AC. Anti-
TGF-beta treatment prevents skin and lung fibrosis in murine
sclerodermatous graft-versus-host disease: a model for human
scleroderma. Journal of immunology 163: 5693-5699, 1999.
255. McDonald GB. Review article: management of hepatic disease
following haematopoietic cell transplant. Alimentary pharma-
cology & therapeutics 24: 441-452, 2006.
256. Mello M, Tanaka C, and Dulley FL. Effects of an exercise pro-
gram on muscle performance in patients undergoing allogene-
ic bone marrow transplantation. Bone marrow transplantation
32: 723-728, 2003.
257. Messina C, Locatelli F, Lanino E, Uderzo C, Zacchello G,
Cesaro S, Pillon M, Perotti C, Del Fante C, Faraci M, Rivabel-
la L, Calore E, De Stefano P, Zecca M, Giorgiani G, Brugiolo
A, Balduzzi A, Dini G, Zanesco L, and Dall'Amico R. Extra-
corporeal photochemotherapy for paediatric patients with
graft-versus-host disease after haematopoietic stem cell trans-
plantation. British journal of haematology 122: 118-127, 2003.
258. Mielcarek M, Storer BE, Boeckh M, Carpenter PA, McDonald
GB, Deeg HJ, Nash RA, Flowers ME, Doney K, Lee S, Marr
KA, Furlong T, Storb R, Appelbaum FR, and Martin PJ. Initial
therapy of acute graft-versus-host disease with low-dose pred-
nisone does not compromise patient outcomes. Blood 113:
2888-2894, 2009.
259. Miklos DB, Kim HT, Miller KH, Guo L, Zorn E, Lee SJ,
Hochberg EP, Wu CJ, Alyea EP, Cutler C, Ho V, Soiffer RJ,
Antin JH, and Ritz J. Antibody responses to H-Y minor histo-
compatibility antigens correlate with chronic graft-versus-host
disease and disease remission. Blood 105: 2973-2978, 2005.
260. Miklos DB, Kim HT, Zorn E, Hochberg EP, Guo L, Mattes-
Ritz A, Viatte S, Soiffer RJ, Antin JH, and Ritz J. Antibody
response to DBY minor histocompatibility antigen is induced
after allogeneic stem cell transplantation and in healthy female
donors. Blood 103: 353-359, 2004.
261. Miller JP, Stadanlick JE, and Cancro MP. Space, selection, and
surveillance: setting boundaries with BLyS. Journal of
immunology 176: 6405-6410, 2006.
262. Mohty M, Marchetti N, El-Cheikh J, Faucher C, Furst S, and
Blaise D. Rituximab as salvage therapy for refractory chronic
GVHD. Bone marrow transplantation 41: 909-911, 2008.
263. Mookerjee B, Altomonte V, and Vogelsang G. Salvage therapy
for refractory chronic graft-versus-host disease with mycophe-
nolate mofetil and tacrolimus. Bone marrow transplantation
24: 517-520, 1999.
264. Moon JH, Lee SJ, Kim JG, Chae YS, Kim SN, Kang BW, Suh
JS, Lee KS, and Sohn SK. Clinical significance of autoanti-
body expression in allogeneic stem-cell recipients. Transplan-
tation 88: 242-250, 2009.
265. Moreno-Romero JA, Fernandez-Aviles F, Carreras E, Rovira
M, Martinez C, and Mascaro JM, Jr. Imatinib as a potential
treatment for sclerodermatous chronic graft-vs-host disease.
Archives of dermatology 144: 1106-1109, 2008.
266. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, and
Coffman RL. Two types of murine helper T cell clone. I. Defi-
nition according to profiles of lymphokine activities and
secreted proteins. Journal of immunology 136: 2348-2357,
1986.
267. Murai M, Yoneyama H, Ezaki T, Suematsu M, Terashima Y,
Harada A, Hamada H, Asakura H, Ishikawa H, and Matsushi-
ma K. Peyer's patch is the essential site in initiating murine
acute and lethal graft-versus-host reaction. Nature immunolo-
gy 4: 154-160, 2003.
268. Murai M, Yoneyama H, Harada A, Yi Z, Vestergaard C, Guo B,
Suzuki K, Asakura H, and Matsushima K. Active participation
of CCR5(+)CD8(+) T lymphocytes in the pathogenesis of liver
injury in graft-versus-host disease. The Journal of clinical
investigation 104: 49-57, 1999.
269. Murase T, Anscher MS, Petros WP, Peters WP, and Jirtle RL.
Changes in plasma transforming growth factor beta in
response to high-dose chemotherapy for stage II breast cancer:
possible implications for the prevention of hepatic veno-occlu-
sive disease and pulmonary drug toxicity. Bone marrow trans-
plantation 15: 173-178, 1995.
270. Murata M, Nakasone H, Kanda J, Nakane T, Furukawa T,
Fukuda T, Mori T, Taniguchi S, Eto T, Ohashi K, Hino M,
Inoue M, Ogawa H, Atsuta Y, Nagamura-Inoue T, Yabe H,
Morishima Y, Sakamaki H, and Suzuki R. Clinical factors pre-
dicting the response of acute graft-versus-host disease to corti-
costeroid therapy: an analysis from the GVHD Working Group
of the Japan Society for Hematopoietic Cell Transplantation.
Biology of blood and marrow transplantation : journal of the
American Society for Blood and Marrow Transplantation 19:
1183-1189, 2013.
271. Muroi K, Miyamura K, Ohashi K, Murata M, Eto T,
Kobayashi N, Taniguchi S, Imamura M, Ando K, Kato S, Mori
T, Teshima T, Mori M, and Ozawa K. Unrelated allogeneic
bone marrow-derived mesenchymal stem cells for steroid-
refractory acute graft-versus-host disease: a phase I/II study.
International journal of hematology 98: 206-213, 2013.
272. Murphy WJ, Welniak LA, Taub DD, Wiltrout RH, Taylor PA,
Vallera DA, Kopf M, Young H, Longo DL, and Blazar BR.
Differential effects of the absence of interferon-gamma and
IL-4 in acute graft-versus-host disease after allogeneic bone
marrow transplantation in mice. The Journal of clinical inves-
tigation 102: 1742-1748, 1998.
273. Nestel FP, Greene RN, Kichian K, Ponka P, and Lapp WS.
Activation of macrophage cytostatic effector mechanisms dur-
ing acute graft-versus-host disease: release of intracellular iron
and nitric oxide-mediated cytostasis. Blood 96: 1836-1843,
2000.
106 •   Graft-versus-host disease and exercise
EIR 21 2015
274. Nevo S, Enger C, Swan V, Wojno KJ, Fuller AK, Altomonte V,
Braine HG, Noga SJ, and Vogelsang GB. Acute bleeding after
allogeneic bone marrow transplantation: association with graft
versus host disease and effect on survival. Transplantation 67:
681-689, 1999.
275. New JY, Li B, Koh WP, Ng HK, Tan SY, Yap EH, Chan SH,
and Hu HZ. T cell infiltration and chemokine expression: rele-
vance to the disease localization in murine graft-versus-host
disease. Bone marrow transplantation 29: 979-986, 2002.
276. Nikolic B, Lee S, Bronson RT, Grusby MJ, and Sykes M. Th1
and Th2 mediate acute graft-versus-host disease, each with
distinct end-organ targets. The Journal of clinical investigation
105: 1289-1298, 2000.
277. Nishimori H, Maeda Y, Teshima T, Sugiyama H, Kobayashi K,
Yamasuji Y, Kadohisa S, Uryu H, Takeuchi K, Tanaka T,
Yoshino T, Iwakura Y, and Tanimoto M. Synthetic retinoid
Am80 ameliorates chronic graft-versus-host disease by down-
regulating Th1 and Th17. Blood 119: 285-295, 2012.
278. Nurieva R, Yang XO, Martinez G, Zhang Y, Panopoulos AD,
Ma L, Schluns K, Tian Q, Watowich SS, Jetten AM, and Dong
C. Essential autocrine regulation by IL-21 in the generation of
inflammatory T cells. Nature 448: 480-483, 2007.
279. Ochs LA, Blazar BR, Roy J, Rest EB, and Weisdorf DJ.
Cytokine expression in human cutaneous chronic graft-versus-
host disease. Bone marrow transplantation 17: 1085-1092, 1996.
280. Oda K, Nakaseko C, Ozawa S, Nishimura M, Saito Y, Yoshiba
F, Yamashita T, Fujita H, Takasaki H, Kanamori H, Maruta A,
Sakamaki H, Okamoto S, and Kanto Study Group for Cell T.
Fasciitis and myositis: an analysis of muscle-related complica-
tions caused by chronic GVHD after allo-SCT. Bone marrow
transplantation 43: 159-167, 2009.
281. Okamoto M, Okano A, Akamatsu S, Ashihara E, Inaba T, Tak-
enaka H, Katoh N, Kishimoto S, and Shimazaki C. Rituximab
is effective for steroid-refractory sclerodermatous chronic
graft-versus-host disease. Leukemia 20: 172-173, 2006.
282. Olivieri A, Cimminiello M, Corradini P, Mordini N, Fedele R,
Selleri C, Onida F, Patriarca F, Pavone E, Svegliati S, Gabriel-
li A, Bresciani P, Nuccorini R, Pascale S, Coluzzi S, Pane F,
Poloni A, Olivieri J, Leoni P, and Bacigalupo A. Long-term
outcome and prospective validation of NIH response criteria in
39 patients receiving imatinib for steroid-refractory chronic
GVHD. Blood 122: 4111-4118, 2013.
283. Olivieri A, Locatelli F, Zecca M, Sanna A, Cimminiello M,
Raimondi R, Gini G, Mordini N, Balduzzi A, Leoni P, Gabriel-
li A, and Bacigalupo A. Imatinib for refractory chronic graft-
versus-host disease with fibrotic features. Blood 114: 709-718,
2009.
284. Owsianowski M, Gollnick H, Siegert W, Schwerdtfeger R, and
Orfanos CE. Successful treatment of chronic graft-versus-host
disease with extracorporeal photopheresis. Bone marrow
transplantation 14: 845-848, 1994.
285. Palmer LA, Sale GE, Balogun JI, Li D, Jones D, Molldrem JJ,
Storb RF, and Ma Q. Chemokine receptor CCR5 mediates
alloimmune responses in graft-versus-host disease. Biology of
blood and marrow transplantation : journal of the American
Society for Blood and Marrow Transplantation 16: 311-319,
2010.
286. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH,
Wang Y, Hood L, Zhu Z, Tian Q, and Dong C. A distinct line-
age of CD4 T cells regulates tissue inflammation by producing
interleukin 17. Nature immunology 6: 1133-1141, 2005.
287. Parker PM, Chao N, Nademanee A, O'Donnell MR, Schmidt
GM, Snyder DS, Stein AS, Smith EP, Molina A, Stepan DE,
Kashyap A, Planas I, Spielberger R, Somlo G, Margolin K,
Zwingenberger K, Wilsman K, Negrin RS, Long GD, Niland JC,
Blume KG, and Forman SJ. Thalidomide as salvage therapy for
chronic graft-versus-host disease. Blood 86: 3604-3609, 1995.
288. Pasquini MC, Wang Z, Horowitz MM, and Gale RP. 2010
report from the Center for International Blood and Marrow
Transplant Research (CIBMTR): current uses and outcomes of
hematopoietic cell transplants for blood and bone marrow dis-
orders. Clinical transplants 87-105, 2010.
289. Patriarca F, Skert C, Sperotto A, Zaja F, Falleti E, Mestroni R,
Kikic F, Calistri E, Fili C, Geromin A, Cerno M, and Fanin R.
The development of autoantibodies after allogeneic stem cell
transplantation is related with chronic graft-vs-host disease
and immune recovery. Experimental hematology 34: 389-396,
2006.
290. Patriarca F, Sperotto A, Damiani D, Morreale G, Bonifazi F,
Olivieri A, Ciceri F, Milone G, Cesaro S, Bandini G, Dini G,
Corradini P, and Fanin R. Infliximab treatment for steroid-
refractory acute graft-versus-host disease. Haematologica 89:
1352-1359, 2004.
291. Perales MA, Ishill N, Lomazow WA, Weinstock DM,
Papadopoulos EB, Dastigir H, Chiu M, Boulad F, Castro-
Malaspina HR, Heller G, Jakubowski AA, O'Reilly RJ, Small
TN, Young JW, and Kernan NA. Long-term follow-up of
patients treated with daclizumab for steroid-refractory acute
graft-vs-host disease. Bone marrow transplantation 40: 481-
486, 2007.
292. Perez-Simon JA, Lopez-Villar O, Andreu EJ, Rifon J, Muntion
S, Campelo MD, Sanchez-Guijo FM, Martinez C, Valcarcel D,
and Canizo CD. Mesenchymal stem cells expanded in vitro
with human serum for the treatment of acute and chronic graft-
versus-host disease: results of a phase I/II clinical trial.
Haematologica 96: 1072-1076, 2011.
293. Perfetti P, Carlier P, Strada P, Gualandi F, Occhini D, Van Lint
MT, Ibatici A, Lamparelli T, Bruno B, Raiola AM, Dominietto
A, Di Grazia C, Bregante S, Zia S, Ferrari GM, Stura P,
Pogliani E, and Bacigalupo A. Extracorporeal photopheresis
for the treatment of steroid refractory acute GVHD. Bone mar-
row transplantation 42: 609-617, 2008.
294. Perseghin P, Dassi M, Balduzzi A, Rovelli A, Bonanomi S, and
Uderzo C. Mononuclear cell collection in patients undergoing
extra-corporeal photo-chemotherapy for acute and chronic
graft-vs.-host-disease (GvHD): comparison between COBE
Spectra version 4.7 and 6.0 (AutoPBSC). Journal of clinical
apheresis 17: 65-71, 2002.
295. Perseghin P, Galimberti S, Balduzzi A, Bonanomi S, Baldini V,
Rovelli A, Dassi M, Rambaldi A, Castagna L, Corti P, Pogliani
EM, and Uderzo C. Extracorporeal photochemotherapy for the
treatment of chronic graft-versus-host disease: trend for a pos-
sible cell dose-related effect? Therapeutic apheresis and dialy-
sis : official peer-reviewed journal of the International Society
for Apheresis, the Japanese Society for Apheresis, the Japan-
ese Society for Dialysis Therapy 11: 85-93, 2007.
296. Perutelli P, Rivabella L, Lanino E, Pistoia V, and Dini G. ATP
downregulation in mononuclear cells from children with graft-
versus-host disease following extracorporeal photochemother-
apy. Haematologica 87: 335-336, 2002.
297. Peters A, Lee Y, and Kuchroo VK. The many faces of Th17
cells. Current opinion in immunology 23: 702-706, 2011.
Graft-versus-host disease and exercise •   107
EIR 21 2015
298. Pidala J, Kim J, Perkins J, Field T, Fernandez H, Perez L,
Ayala E, Kharfan-Dabaja M, and Anasetti C. Mycophenolate
mofetil for the management of steroid-refractory acute graft vs
host disease. Bone marrow transplantation 45: 919-924, 2010.
299. Pidala J, Kim J, Roman-Diaz J, Shapiro J, Nishihori T, Book-
out R, Anasetti C, and Kharfan-Dabaja MA. Pentostatin as res-
cue therapy for glucocorticoid-refractory acute and chronic
graft-versus-host disease. Annals of transplantation : quarterly
of the Polish Transplantation Society 15: 21-29, 2010.
300. Piguet PF, Grau GE, Allet B, and Vassalli P. Tumor necrosis
factor/cachectin is an effector of skin and gut lesions of the
acute phase of graft-vs.-host disease. The Journal of experi-
mental medicine 166: 1280-1289, 1987.
301. Pinana JL, Valcarcel D, Martino R, Moreno ME, Sureda A,
Briones J, Brunet S, and Sierra J. Encouraging results with
inolimomab (anti-IL-2 receptor) as treatment for refractory
acute graft-versus-host disease. Biology of blood and marrow
transplantation : journal of the American Society for Blood
and Marrow Transplantation 12: 1135-1141, 2006.
302. Przepiorka D, Kernan NA, Ippoliti C, Papadopoulos EB,
Giralt S, Khouri I, Lu JG, Gajewski J, Durett A, Cleary K,
Champlin R, Andersson BS, and Light S. Daclizumab, a
humanized anti-interleukin-2 receptor alpha chain antibody,
for treatment of acute graft-versus-host disease. Blood 95: 83-
89, 2000.
303. Pusic I, Pavletic SZ, Kessinger A, Tarantolo SR, and Bishop
MR. Pseudoautologous blood stem cell transplantation for
refractory chronic graft-versus-host disease. Bone marrow
transplantation 29: 709-710, 2002.
304. Quaranta S, Shulman H, Ahmed A, Shoenfeld Y, Peter J,
McDonald GB, Van de Water J, Coppel R, Ostlund C, Worman
HJ, Rizzetto M, Tsuneyama K, Nakanuma Y, Ansari A,
Locatelli F, Paganin S, Rosina F, Manns M, and Gershwin ME.
Autoantibodies in human chronic graft-versus-host disease
after hematopoietic cell transplantation. Clinical immunology
91: 106-116, 1999.
305. Rao K, Rao A, Karlsson H, Jagani M, Veys P, and Amrolia PJ.
Improved survival and preserved antiviral responses after
combination therapy with daclizumab and infliximab in
steroid-refractory graft-versus-host disease. Journal of pedi-
atric hematology/oncology 31: 456-461, 2009.
306. Ratajczak P, Janin A, Peffault de Latour R, Leboeuf C,
Desveaux A, Keyvanfar K, Robin M, Clave E, Douay C, Quin-
quenel A, Pichereau C, Bertheau P, Mary JY, and Socie G.
Th17/Treg ratio in human graft-versus-host disease. Blood
116: 1165-1171, 2010.
307. Ratanatharathorn V, Ayash L, Lazarus HM, Fu J, and Uberti JP.
Chronic graft-versus-host disease: clinical manifestation and
therapy. Bone marrow transplantation 28: 121-129, 2001.
308. Ratanatharathorn V, Ayash L, Reynolds C, Silver S, Reddy P,
Becker M, Ferrara JL, and Uberti JP. Treatment of chronic
graft-versus-host disease with anti-CD20 chimeric monoclonal
antibody. Biology of blood and marrow transplantation : jour-
nal of the American Society for Blood and Marrow Transplan-
tation 9: 505-511, 2003.
309. Ratanatharathorn V, Carson E, Reynolds C, Ayash LJ, Levine
J, Yanik G, Silver SM, Ferrara JL, and Uberti JP. Anti-CD20
chimeric monoclonal antibody treatment of refractory
immune-mediated thrombocytopenia in a patient with chronic
graft-versus-host disease. Annals of internal medicine 133:
275-279, 2000.
310. Recher C, Beyne-Rauzy O, Demur C, Chicanne G, Dos Santos
C, Mas VM, Benzaquen D, Laurent G, Huguet F, and Payras-
tre B. Antileukemic activity of rapamycin in acute myeloid
leukemia. Blood 105: 2527-2534, 2005.
311. Reddy P. Pathophysiology of acute graft-versus-host disease.
Hematological oncology 21: 149-161, 2003.
312. Ribeiro RM, and Perelson AS. Determining thymic output
quantitatively: using models to interpret experimental T-cell
receptor excision circle (TREC) data. Immunological reviews
216: 21-34, 2007.
313. Ringden O, Uzunel M, Rasmusson I, Remberger M, Sundberg
B, Lonnies H, Marschall HU, Dlugosz A, Szakos A, Hassan Z,
Omazic B, Aschan J, Barkholt L, and Le Blanc K. Mesenchy-
mal stem cells for treatment of therapy-resistant graft-versus-
host disease. Transplantation 81: 1390-1397, 2006.
314. Ritchie D, Seconi J, Wood C, Walton J, and Watt V. Prospec-
tive monitoring of tumor necrosis factor alpha and interferon
gamma to predict the onset of acute and chronic graft-versus-
host disease after allogeneic stem cell transplantation. Biology
of blood and marrow transplantation : journal of the American
Society for Blood and Marrow Transplantation 11: 706-712,
2005.
315. Rodriguez V, Anderson PM, Trotz BA, Arndt CA, Allen JA,
and Khan SP. Use of infliximab-daclizumab combination for
the treatment of acute and chronic graft-versus-host disease of
the liver and gut. Pediatric blood & cancer 49: 212-215, 2007.
316. Rossetti F, Dall'Amico R, Crovetti G, Messina C, Montini G,
Dini G, Locatelli F, Argiolu F, Miniero R, and Zacchello G.
Extracorporeal photochemotherapy for the treatment of graft-
versus-host disease. Bone marrow transplantation 18 Suppl 2:
175-181, 1996.
317. Rouquette-Gally AM, Boyeldieu D, Prost AC, and Gluckman
E. Autoimmunity after allogeneic bone marrow transplanta-
tion. A study of 53 long-term-surviving patients. Transplanta-
tion 46: 238-240, 1988.
318. Rovelli A, Arrigo C, Nesi F, Balduzzi A, Nicolini B, Locasci-
ulli A, Vassallo E, Miniero R, and Uderzo C. The role of
thalidomide in the treatment of refractory chronic graft-versus-
host disease following bone marrow transplantation in chil-
dren. Bone marrow transplantation 21: 577-581, 1998.
319. Roy J, McGlave PB, Filipovich AH, Miller WJ, Blazar BR,
Ramsay NK, Kersey JH, and Weisdorf DJ. Acute graft-versus-
host disease following unrelated donor marrow transplanta-
tion: failure of conventional therapy. Bone marrow transplan-
tation 10: 77-82, 1992.
320. Rozmus J, Schultz KR, Wynne K, Kariminia A, Satyanarayana
P, Krailo M, Grupp SA, Gilman AL, and Goldman FD. Early
and late extensive chronic graft-versus-host disease in children
is characterized by different Th1/Th2 cytokine profiles: find-
ings of the Children's Oncology Group Study ASCT0031.
Biology of blood and marrow transplantation : journal of the
American Society for Blood and Marrow Transplantation 17:
1804-1813, 2011.
321. Rubtsov YP, and Rudensky AY. TGFbeta signalling in control
of T-cell-mediated self-reactivity. Nature reviews Immunology
7: 443-453, 2007.
322. Ruiz-Arguelles GJ, Gil-Beristain J, Magana M, and Ruiz-Del-
gado GJ. Alemtuzumab-induced resolution of refractory cuta-
neous chronic graft-versus-host disease. Biology of blood and
marrow transplantation : journal of the American Society for
Blood and Marrow Transplantation 14: 7-9, 2008.
108 •   Graft-versus-host disease and exercise
EIR 21 2015
323. Rzepecki P, Barzal J, Sarosiek T, Oborska S, and Szczylik C.
How can we help patients with refractory chronic graft versus
host disease- single centre experience. Neoplasma 54: 431-
436, 2007.
324. Sackstein R. A revision of Billingham's tenets: the central role
of lymphocyte migration in acute graft-versus-host disease.
Biology of blood and marrow transplantation : journal of the
American Society for Blood and Marrow Transplantation 12:
2-8, 2006.
325. Sakoda Y, Hashimoto D, Asakura S, Takeuchi K, Harada M,
Tanimoto M, and Teshima T. Donor-derived thymic-dependent
T cells cause chronic graft-versus-host disease. Blood 109:
1756-1764, 2007.
326. Salvaneschi L, Perotti C, Zecca M, Bernuzzi S, Viarengo G,
Giorgiani G, Del Fante C, Bergamaschi P, Maccario R, Pession
A, and Locatelli F. Extracorporeal photochemotherapy for
treatment of acute and chronic GVHD in childhood. Transfu-
sion 41: 1299-1305, 2001.
327. Sarantopoulos S, Stevenson KE, Kim HT, Bhuiya NS, Cutler
CS, Soiffer RJ, Antin JH, and Ritz J. High levels of B-cell acti-
vating factor in patients with active chronic graft-versus-host
disease. Clinical cancer research : an official journal of the
American Association for Cancer Research 13: 6107-6114,
2007.
328. Sarantopoulos S, Stevenson KE, Kim HT, Cutler CS, Bhuiya
NS, Schowalter M, Ho VT, Alyea EP, Koreth J, Blazar BR,
Soiffer RJ, Antin JH, and Ritz J. Altered B-cell homeostasis
and excess BAFF in human chronic graft-versus-host disease.
Blood 113: 3865-3874, 2009.
329. Sato K, Nakaoka T, Yamashita N, Yagita H, Kawasaki H,
Morimoto C, Baba M, and Matsuyama T. TRAIL-transduced
dendritic cells protect mice from acute graft-versus-host dis-
ease and leukemia relapse. Journal of immunology 174: 4025-
4033, 2005.
330. Scarisbrick JJ, Taylor P, Holtick U, Makar Y, Douglas K,
Berlin G, Juvonen E, Marshall S, and Photopheresis Expert G.
U.K. consensus statement on the use of extracorporeal photo-
pheresis for treatment of cutaneous T-cell lymphoma and
chronic graft-versus-host disease. The British journal of der-
matology 158: 659-678, 2008.
331. Schmaltz C, Alpdogan O, Kappel BJ, Muriglan SJ, Rotolo JA,
Ongchin J, Willis LM, Greenberg AS, Eng JM, Crawford JM,
Murphy GF, Yagita H, Walczak H, Peschon JJ, and van den
Brink MR. T cells require TRAIL for optimal graft-versus-
tumor activity. Nature medicine 8: 1433-1437, 2002.
332. Schmidt-Hieber M, Fietz T, Knauf W, Uharek L, Hopfen-
muller W, Thiel E, and Blau IW. Efficacy of the interleukin-2
receptor antagonist basiliximab in steroid-refractory acute
graft-versus-host disease. British journal of haematology 130:
568-574, 2005.
333. Schnitzler M, Hasskarl J, Egger M, Bertz H, and Finke J. Suc-
cessful treatment of severe acute intestinal graft-versus-host
resistant to systemic and topical steroids with alemtuzumab.
Biology of blood and marrow transplantation : journal of the
American Society for Blood and Marrow Transplantation 15:
910-918, 2009.
334. Schub N, Gunther A, Schrauder A, Claviez A, Ehlert C, Gra-
matzki M, and Repp R. Therapy of steroid-refractory acute
GVHD with CD52 antibody alemtuzumab is effective. Bone
marrow transplantation 46: 143-147, 2011.
335. Schultz KR, Miklos DB, Fowler D, Cooke K, Shizuru J, Zorn
E, Holler E, Ferrara J, Shulman H, Lee SJ, Martin P, Filipovich
AH, Flowers ME, Weisdorf D, Couriel D, Lachenbruch PA,
Mittleman B, Vogelsang GB, and Pavletic SZ. Toward bio-
markers for chronic graft-versus-host disease: National Insti-
tutes of Health consensus development project on criteria for
clinical trials in chronic graft-versus-host disease: III. Bio-
marker Working Group Report. Biology of blood and marrow
transplantation : journal of the American Society for Blood
and Marrow Transplantation 12: 126-137, 2006.
336. Schultz KR, Paquet J, Bader S, and HayGlass KT. Require-
ment for B cells in T cell priming to minor histocompatibility
antigens and development of graft-versus-host disease. Bone
marrow transplantation 16: 289-295, 1995.
337. Seaton ED, Szydlo RM, Kanfer E, Apperley JF, and Russell-
Jones R. Influence of extracorporeal photopheresis on clinical
and laboratory parameters in chronic graft-versus-host disease
and analysis of predictors of response. Blood 102: 1217-1223,
2003.
338. Seder RA, Paul WE, Ben-Sasson SZ, LeGros GS, Kagey-
Sobotka A, Finkelman FD, Pierce JH, and Plaut M. Production
of interleukin-4 and other cytokines following stimulation of
mast cell lines and in vivo mast cells/basophils. International
archives of allergy and applied immunology 94: 137-140,
1991.
339. Seggewiss R, and Einsele H. Immune reconstitution after allo-
geneic transplantation and expanding options for
immunomodulation: an update. Blood 115: 3861-3868, 2010.
340. Serody JS, and Hill GR. The IL-17 differentiation pathway and
its role in transplant outcome. Biology of blood and marrow
transplantation : journal of the American Society for Blood
and Marrow Transplantation 18: S56-61, 2012.
341. Shapira MY, Abdul-Hai A, Resnick IB, Bitan M, Tsirigotis P,
Aker M, Gesundheit B, Slavin S, and Or R. Alefacept treat-
ment for refractory chronic extensive GVHD. Bone marrow
transplantation 43: 339-343, 2009.
342. Sharpe AH, and Freeman GJ. The B7-CD28 superfamily.
Nature reviews Immunology 2: 116-126, 2002.
343. Shaughnessy PJ, Bachier C, Grimley M, Freytes CO, Callan-
der NS, Essell JH, Flomenberg N, Selby G, and Lemaistre CF.
Denileukin diftitox for the treatment of steroid-resistant acute
graft-versus-host disease. Biology of blood and marrow trans-
plantation : journal of the American Society for Blood and
Marrow Transplantation 11: 188-193, 2005.
344. She K, Gilman AL, Aslanian S, Shimizu H, Krailo M, Chen Z,
Reid GS, Wall D, Goldman F, and Schultz KR. Altered Toll-
like receptor 9 responses in circulating B cells at the onset of
extensive chronic graft-versus-host disease. Biology of blood
and marrow transplantation : journal of the American Society
for Blood and Marrow Transplantation 13: 386-397, 2007.
345. Shimada M, Onizuka M, Machida S, Suzuki R, Kojima M,
Miyamura K, Kodera Y, Inoko H, and Ando K. Association of
autoimmune disease-related gene polymorphisms with chronic
graft-versus-host disease. British journal of haematology 139:
458-463, 2007.
346. Ship A, May W, and Lucas K. Anti-CD20 monoclonal anti-
body therapy for autoimmune hemolytic anemia following T
cell-depleted, haplo-identical stem cell transplantation. Bone
marrow transplantation 29: 365-366, 2002.
347. Shlomchik WD. Graft-versus-host disease. Nature reviews
Immunology 7: 340-352, 2007.
Graft-versus-host disease and exercise •   109
EIR 21 2015
348. Shlomchik WD, Couzens MS, Tang CB, McNiff J, Robert ME,
Liu J, Shlomchik MJ, and Emerson SG. Prevention of graft
versus host disease by inactivation of host antigen-presenting
cells. Science 285: 412-415, 1999.
349. Shulman HM, Kleiner D, Lee SJ, Morton T, Pavletic SZ,
Farmer E, Moresi JM, Greenson J, Janin A, Martin PJ,
McDonald G, Flowers ME, Turner M, Atkinson J, Lefkowitch
J, Washington MK, Prieto VG, Kim SK, Argenyi Z, Diwan
AH, Rashid A, Hiatt K, Couriel D, Schultz K, Hymes S, and
Vogelsang GB. Histopathologic diagnosis of chronic graft-ver-
sus-host disease: National Institutes of Health Consensus
Development Project on Criteria for Clinical Trials in Chronic
Graft-versus-Host Disease: II. Pathology Working Group
Report. Biology of blood and marrow transplantation : journal
of the American Society for Blood and Marrow Transplanta-
tion 12: 31-47, 2006.
350. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Strik-
er GE, Sale GE, Hackman R, Tsoi MS, Storb R, and Thomas
ED. Chronic graft-versus-host syndrome in man. A long-term
clinicopathologic study of 20 Seattle patients. The American
journal of medicine 69: 204-217, 1980.
351. Sleight BS, Chan KW, Braun TM, Serrano A, and Gilman AL.
Infliximab for GVHD therapy in children. Bone marrow trans-
plantation 40: 473-480, 2007.
352. Small TN, Robinson WH, and Miklos DB. B cells and trans-
plantation: an educational resource. Biology of blood and mar-
row transplantation : journal of the American Society for
Blood and Marrow Transplantation 15: 104-113, 2009.
353. Snover DC, Weisdorf SA, Ramsay NK, McGlave P, and
Kersey JH. Hepatic graft versus host disease: a study of the
predictive value of liver biopsy in diagnosis. Hepatology 4:
123-130, 1984.
354. Snover DC, Weisdorf SA, Vercellotti GM, Rank B, Hutton S,
and McGlave P. A histopathologic study of gastric and small
intestinal graft-versus-host disease following allogeneic bone
marrow transplantation. Human pathology 16: 387-392, 1985.
355. Soiffer R. Immune modulation and chronic graft-versus-host
disease. Bone marrow transplantation 42 Suppl 1: S66-S69,
2008.
356. Sprent J, and Kishimoto H. The thymus and central tolerance.
Transplantation 72: S25-28, 2001.
357. Srinivasan R, Chakrabarti S, Walsh T, Igarashi T, Takahashi Y,
Kleiner D, Donohue T, Shalabi R, Carvallo C, Barrett AJ,
Geller N, and Childs R. Improved survival in steroid-refracto-
ry acute graft versus host disease after non-myeloablative allo-
geneic transplantation using a daclizumab-based strategy with
comprehensive infection prophylaxis. British journal of
haematology 124: 777-786, 2004.
358. Stadler M, Ahlborn R, Kamal H, Diedrich H, Buchholz S,
Eder M, and Ganser A. Limited efficacy of imatinib in severe
pulmonary chronic graft-versus-host disease. Blood 114:
3718-3719; author reply 3719-3720, 2009.
359. Storb R, Antin JH, and Cutler C. Should methotrexate plus cal-
cineurin inhibitors be considered standard of care for prophy-
laxis of acute graft-versus-host disease? Biology of blood and
marrow transplantation : journal of the American Society for
Blood and Marrow Transplantation 16: S18-27, 2010.
360. Storek J, Espino G, Dawson MA, Storer B, Flowers ME, and Mal-
oney DG. Low B-cell and monocyte counts on day 80 are associ-
ated with high infection rates between days 100 and 365 after
allogeneic marrow transplantation. Blood 96: 3290-3293, 2000.
361. Storek J, Ferrara S, Ku N, Giorgi JV, Champlin RE, and Saxon
A. B cell reconstitution after human bone marrow transplanta-
tion: recapitulation of ontogeny? Bone marrow transplantation
12: 387-398, 1993.
362. Sullivan KM. Graft-vs-host disease. In: Thomas' Hematopoiet-
ic Cell Transplantation, edited by Blume KG, Forman SJ, and
Appelbaum FR. Oxford, UK: Blackwell Publishing Ltd, 2004,
p. 635–664.
363. Sullivan KM, Shulman HM, Storb R, Weiden PL, Witherspoon
RP, McDonald GB, Schubert MM, Atkinson K, and Thomas
ED. Chronic graft-versus-host disease in 52 patients: adverse
natural course and successful treatment with combination
immunosuppression. Blood 57: 267-276, 1981.
364. Sullivan KM, Witherspoon RP, Storb R, Deeg HJ, Dahlberg S,
Sanders JE, Appelbaum FR, Doney KC, Weiden P, Anasetti C,
and et al. Alternating-day cyclosporine and prednisone for
treatment of high-risk chronic graft-v-host disease. Blood 72:
555-561, 1988.
365. Svegliati S, Olivieri A, Campelli N, Luchetti M, Poloni A,
Trappolini S, Moroncini G, Bacigalupo A, Leoni P, Avvedi-
mento EV, and Gabrielli A. Stimulatory autoantibodies to
PDGF receptor in patients with extensive chronic graft-versus-
host disease. Blood 110: 237-241, 2007.
366. Swain SL, Weinberg AD, English M, and Huston G. IL-4
directs the development of Th2-like helper effectors. Journal
of immunology 145: 3796-3806, 1990.
367. Syrjala KL, Chapko MK, Vitaliano PP, Cummings C, and Sul-
livan KM. Recovery after allogeneic marrow transplantation:
prospective study of predictors of long-term physical and psy-
chosocial functioning. Bone marrow transplantation 11: 319-
327, 1993.
368. Syrjala KL, Langer S, Abrams J, Storer B, and Martin P. Phys-
ical and mental recovery after hematopoietic stem cell trans-
plantation. Discovery medicine 4: 263-269, 2004.
369. Syrjala KL, Langer SL, Abrams JR, Storer BE, and Martin PJ.
Late effects of hematopoietic cell transplantation among 10-
year adult survivors compared with case-matched controls.
Journal of clinical oncology : official journal of the American
Society of Clinical Oncology 23: 6596-6606, 2005.
370. Szabolcs P, Reese M, Yancey KB, Hall RP, and Kurtzberg J.
Combination treatment of bullous pemphigoid with anti-CD20
and anti-CD25 antibodies in a patient with chronic graft-ver-
sus-host disease. Bone marrow transplantation 30: 327-329,
2002.
371. Tanaka J, Imamura M, Kasai M, Hashino S, Kobayashi S,
Noto S, Higa T, Sakurada K, and Asaka M. The important bal-
ance between cytokines derived from type 1 and type 2 helper
T cells in the control of graft-versus-host disease. Bone mar-
row transplantation 19: 571-576, 1997.
372. Tanaka J, Imamura M, Kasai M, Hashino S, Kobayashi S,
Noto S, Higa T, Sakurada K, and Asaka M. Th2 cytokines (IL-
4, IL-10 and IL-13) and IL-12 mRNA expression by con-
canavalin A-stimulated peripheral blood mononuclear cells
during chronic graft-versus-host disease. European journal of
haematology 57: 111-113, 1996.
373. Tazzari PL, Gobbi M, Zauli D, Tassinari A, Crespi C, Miseroc-
chi F, Dinota A, Bandini G, Ricci P, and Tura S. Close associa-
tion between antibodies to cytoskeletal intermediate filaments,
and chronic graft-versus-host disease. Transplantation 44: 234-
236, 1987.
110 •   Graft-versus-host disease and exercise
EIR 21 2015
374. Teshima T, Maeda Y, and Ozaki K. Regulatory T cells and IL-
17-producing cells in graft-versus-host disease. Immunothera-
py 3: 833-852, 2011.
375. Teshima T, Nagafuji K, Henzan H, Miyamura K, Takase K,
Hidaka M, Miyamoto T, Takenaka K, Akashi K, and Harada
M. Rituximab for the treatment of corticosteroid-refractory
chronic graft-versus-host disease. International journal of
hematology 90: 253-260, 2009.
376. Thoma MD, Huneke TJ, DeCook LJ, Johnson ND, Wiegand
RA, Litzow MR, Hogan WJ, Porrata LF, and Holtan SG.
Peripheral blood lymphocyte and monocyte recovery and sur-
vival in acute leukemia postmyeloablative allogeneic
hematopoietic stem cell transplant. Biol Blood Marrow Trans-
plant 18: 600-607, 2012.
377. Thomas E, Storb R, Clift RA, Fefer A, Johnson FL, Neiman
PE, Lerner KG, Glucksberg H, and Buckner CD. Bone-mar-
row transplantation (first of two parts). The New England jour-
nal of medicine 292: 832-843, 1975.
378. Thomas ED. Bone marrow transplantation: a review. Seminars
in hematology 36: 95-103, 1999.
379. Thomas ED. A history of haemopoietic cell transplantation.
British journal of haematology 105: 330-339, 1999.
380. Thomas ED, Lochte HL, Jr., Cannon JH, Sahler OD, and Fer-
rebee JW. Supralethal whole body irradiation and isologous
marrow transplantation in man. The Journal of clinical investi-
gation 38: 1709-1716, 1959.
381. Thomas ED, Lochte HL, Jr., Lu WC, and Ferrebee JW. Intra-
venous infusion of bone marrow in patients receiving radiation
and chemotherapy. The New England journal of medicine 257:
491-496, 1957.
382. Tivol E, Komorowski R, and Drobyski WR. Emergent autoimmu-
nity in graft-versus-host disease. Blood 105: 4885-4891, 2005.
383. Toor AA, Stiff PJ, Nickoloff BJ, Rodriguez T, Klein JL, and
Gordon KB. Alefacept in corticosteroid refractory graft versus
host disease: early results indicate promising activity. The
Journal of dermatological treatment 18: 13-18, 2007.
384. Toubai T, Sun Y, and Reddy P. GVHD pathophysiology: is
acute different from chronic? Best practice & research Clinical
haematology 21: 101-117, 2008.
385. Tran J, Norder EE, Diaz PT, Phillips GS, Elder P, Devine SM,
and Wood KL. Pulmonary rehabilitation for bronchiolitis
obliterans syndrome after hematopoietic stem cell transplanta-
tion. Biology of blood and marrow transplantation : journal of
the American Society for Blood and Marrow Transplantation
18: 1250-1254, 2012.
386. Tsoi MS, Storb R, Jones E, Weiden PL, Shulman H, Wither-
spoon R, Atkinson K, and Thomas ED. Deposition of IgM and
complement at the dermoepidermal junction in acute and
chronic cutaneous graft-vs-host disease in man. Journal of
immunology 120: 1485-1492, 1978.
387. Tzakis AG, Abu-Elmagd K, Fung JJ, Bloom EJ, Nour B, Greif
F, and Starzl TE. FK 506 rescue in chronic graft-versus-host-
disease after bone marrow transplantation. Transplantation
proceedings 23: 3225-3227, 1991.
388. Uberti JP, Ayash L, Ratanatharathorn V, Silver S, Reynolds C,
Becker M, Reddy P, Cooke KR, Yanik G, Whitfield J, Jones D,
Hutchinson R, Braun T, Ferrara JL, and Levine JE. Pilot trial
on the use of etanercept and methylprednisolone as primary
treatment for acute graft-versus-host disease. Biology of blood
and marrow transplantation : journal of the American Society
for Blood and Marrow Transplantation 11: 680-687, 2005.
389. Umland SP, Razac S, Nahrebne DK, and Seymour BW. Effects
of in vivo administration of interferon (IFN)-gamma, anti-
IFN-gamma, or anti-interleukin-4 monoclonal antibodies in
chronic autoimmune graft-versus-host disease. Clinical
immunology and immunopathology 63: 66-73, 1992.
390. Ussowicz M, Musial J, Mielcarek M, Tomaszewska A,
Nasilowska-Adamska B, Kalwak K, Gorczynska E, Marianska
B, and Chybicka A. Steroid-sparing effect of extracorporeal
photopheresis in the therapy of graft-versus-host disease after
allogeneic hematopoietic stem cell transplantation. Transplan-
tation proceedings 45: 3375-3380, 2013.
391. van den Brink MR, and Burakoff SJ. Cytolytic pathways in
haematopoietic stem-cell transplantation. Nature reviews
Immunology 2: 273-281, 2002.
392. Van Lint MT, Milone G, Leotta S, Uderzo C, Scime R, Dallor-
so S, Locasciulli A, Guidi S, Mordini N, Sica S, Cudillo L,
Fagioli F, Selleri C, Bruno B, Arcese W, and Bacigalupo A.
Treatment of acute graft-versus-host disease with pred-
nisolone: significant survival advantage for day +5 responders
and no advantage for nonresponders receiving anti-thymocyte
globulin. Blood 107: 4177-4181, 2006.
393. Van Lint MT, Uderzo C, Locasciulli A, Majolino I, Scime R,
Locatelli F, Giorgiani G, Arcese W, Iori AP, Falda M, Bosi A,
Miniero R, Alessandrino P, Dini G, Rotoli B, and Bacigalupo
A. Early treatment of acute graft-versus-host disease with
high- or low-dose 6-methylprednisolone: a multicenter ran-
domized trial from the Italian Group for Bone Marrow Trans-
plantation. Blood 92: 2288-2293, 1998.
394. Varona R, Cadenas V, Gomez L, Martinez AC, and Marquez
G. CCR6 regulates CD4+ T-cell-mediated acute graft-versus-
host disease responses. Blood 106: 18-26, 2005.
395. Vasconcelos L, Vieira EC, Minicucci EM, Salvio AG, Souza
MP, Marques ME, and Marques SA. Chronic graft-versus-host
disease: clinical presentation of multiple lesions of lichenoid
and atrophic pattern. Anais brasileiros de dermatologia 88:
799-802, 2013.
396. Veldhoen M, Hocking RJ, Flavell RA, and Stockinger B. Sig-
nals mediated by transforming growth factor-beta initiate
autoimmune encephalomyelitis, but chronic inflammation is
needed to sustain disease. Nature immunology 7: 1151-1156,
2006.
397. Vigorito AC, Bouzas LF, Moreira MC, Funke VA, Colturato
VA, Pedro A, Souza CV, Nunes EC, Miranda EC, Camacho K,
Mauad MA, Correa ME, Silva MD, Sousa MP, Tavares RD,
Lee SJ, and Flowers ME. A multicenter feasibility study of
chronic graft-versus-host disease according to the National
Institute of Health criteria: efforts to establish a Brazil-Seattle
consortium as a platform for future collaboration in clinical tri-
als. Revista brasileira de hematologia e hemoterapia 33: 283-
289, 2011.
398. Vogelsang GB. How I treat chronic graft-versus-host disease.
Blood 97: 1196-1201, 2001.
399. Vogelsang GB, Farmer ER, Hess AD, Altamonte V,
Beschorner WE, Jabs DA, Corio RL, Levin LS, Colvin OM,
Wingard JR, and et al. Thalidomide for the treatment of chron-
ic graft-versus-host disease. The New England journal of med-
icine 326: 1055-1058, 1992.
400. Vogelsang GB, Lee L, and Bensen-Kennedy DM. Pathogene-
sis and treatment of graft-versus-host disease after bone mar-
row transplant. Annual review of medicine 54: 29-52, 2003.
Graft-versus-host disease and exercise •   111
EIR 21 2015
401. von Bahr L, Batsis I, Moll G, Hagg M, Szakos A, Sundberg B,
Uzunel M, Ringden O, and Le Blanc K. Analysis of tissues
following mesenchymal stromal cell therapy in humans indi-
cates limited long-term engraftment and no ectopic tissue for-
mation. Stem cells 30: 1575-1578, 2012.
402. von Bonin M, Kiani A, Platzbecker U, Schetelig J, Holig K,
Oelschlagel U, Thiede C, Ehninger G, and Bornhauser M.
Third-party mesenchymal stem cells as part of the manage-
ment of graft-failure after haploidentical stem cell transplanta-
tion. Leukemia research 33: e215-217, 2009.
403. von Bonin M, Oelschlagel U, Radke J, Stewart M, Ehninger
G, Bornhauser M, and Platzbecker U. Treatment of chronic
steroid-refractory graft-versus-host disease with low-dose rit-
uximab. Transplantation 86: 875-879, 2008.
404. von Bonin M, Stolzel F, Goedecke A, Richter K, Wuschek N,
Holig K, Platzbecker U, Illmer T, Schaich M, Schetelig J,
Kiani A, Ordemann R, Ehninger G, Schmitz M, and Born-
hauser M. Treatment of refractory acute GVHD with third-
party MSC expanded in platelet lysate-containing medium.
Bone marrow transplantation 43: 245-251, 2009.
405. Waldman E, Lu SX, Hubbard VM, Kochman AA, Eng JM,
Terwey TH, Muriglan SJ, Kim TD, Heller G, Murphy GF, Liu
C, Alpdogan O, and van den Brink MR. Absence of beta7 inte-
grin results in less graft-versus-host disease because of
decreased homing of alloreactive T cells to intestine. Blood
107: 1703-1711, 2006.
406. Walsh NP, Gleeson M, Shephard RJ, Gleeson M, Woods JA,
Bishop NC, Fleshner M, Green C, Pedersen BK, Hoffman-
Goetz L, Rogers CJ, Northoff H, Abbasi A, and Simon P. Posi-
tion statement. Part one: Immune function and exercise. Exer-
cise immunology review 17: 6-63, 2011.
407. Wang JZ, Liu KY, Xu LP, Liu DH, Han W, Chen H, Chen YH,
Zhang XH, Zhao T, Wang Y, and Huang XJ. Basiliximab for
the treatment of steroid-refractory acute graft-versus-host dis-
ease after unmanipulated HLA-mismatched/haploidentical
hematopoietic stem cell transplantation. Transplantation pro-
ceedings 43: 1928-1933, 2011.
408. Watson M, Wheatley K, Harrison GA, Zittoun R, Gray RG,
Goldstone AH, and Burnett AK. Severe adverse impact on sex-
ual functioning and fertility of bone marrow transplantation,
either allogeneic or autologous, compared with consolidation
chemotherapy alone: analysis of the MRC AML 10 trial. Can-
cer 86: 1231-1239, 1999.
409. Weaver CT, Hatton RD, Mangan PR, and Harrington LE. IL-
17 family cytokines and the expanding diversity of effector T
cell lineages. Annual review of immunology 25: 821-852,
2007.
410. Wechalekar A, Cranfield T, Sinclair D, and Ganzckowski M.
Occurrence of autoantibodies in chronic graft vs. host disease
after allogeneic stem cell transplantation. Clinical and labora-
tory haematology 27: 247-249, 2005.
411. Weinberg K, Blazar BR, Wagner JE, Agura E, Hill BJ,
Smogorzewska M, Koup RA, Betts MR, Collins RH, and
Douek DC. Factors affecting thymic function after allogeneic
hematopoietic stem cell transplantation. Blood 97: 1458-1466,
2001.
412. Weisdorf D, Haake R, Blazar B, Miller W, McGlave P, Ram-
say N, Kersey J, and Filipovich A. Treatment of
moderate/severe acute graft-versus-host disease after allogene-
ic bone marrow transplantation: an analysis of clinical risk fea-
tures and outcome. Blood 75: 1024-1030, 1990.
413. Welniak LA, Blazar BR, and Murphy WJ. Immunobiology of
allogeneic hematopoietic stem cell transplantation. Annual
review of immunology 25: 139-170, 2007.
414. Welniak LA, Kuprash DV, Tumanov AV, Panoskaltsis-Mortari
A, Blazar BR, Sun K, Nedospasov SA, and Murphy WJ. Peyer
patches are not required for acute graft-versus-host disease
after myeloablative conditioning and murine allogeneic bone
marrow transplantation. Blood 107: 410-412, 2006.
415. Weng JY, Du X, Geng SX, Peng YW, Wang Z, Lu ZS, Wu SJ,
Luo CW, Guo R, Ling W, Deng CX, Liao PJ, and Xiang AP.
Mesenchymal stem cell as salvage treatment for refractory
chronic GVHD. Bone marrow transplantation 45: 1732-1740,
2010.
416. Wilhelm K, Ganesan J, Muller T, Durr C, Grimm M, Beilhack
A, Krempl CD, Sorichter S, Gerlach UV, Juttner E, Zerweck
A, Gartner F, Pellegatti P, Di Virgilio F, Ferrari D, Kambham
N, Fisch P, Finke J, Idzko M, and Zeiser R. Graft-versus-host
disease is enhanced by extracellular ATP activating P2X7R.
Nature medicine 16: 1434-1438, 2010.
417. Wilson RW, Jacobsen PB, and Fields KK. Pilot study of a
home-based aerobic exercise program for sedentary cancer
survivors treated with hematopoietic stem cell transplantation.
Bone marrow transplantation 35: 721-727, 2005.
418. Willenbacher W, Basara N, Blau IW, Fauser AA, and Kiehl
MG. Treatment of steroid refractory acute and chronic graft-
versus-host disease with daclizumab. British journal of haema-
tology 112: 820-823, 2001.
419. Wiskemann J, Dreger P, Schwerdtfeger R, Bondong A, Huber
G, Kleindienst N, Ulrich CM, and Bohus M. Effects of a partly
self-administered exercise program before, during, and after
allogeneic stem cell transplantation. Blood 117: 2604-2613,
2011.
420. Wolff D, Bertz H, Greinix H, Lawitschka A, Halter J, and
Holler E. The treatment of chronic graft-versus-host disease:
consensus recommendations of experts from Germany, Aus-
tria, and Switzerland. Deutsches Arzteblatt international 108:
732-740, 2011.
421. Wolff D, Gerbitz A, Ayuk F, Kiani A, Hildebrandt GC, Vogel-
sang GB, Elad S, Lawitschka A, Socie G, Pavletic SZ, Holler
E, and Greinix H. Consensus conference on clinical practice in
chronic graft-versus-host disease (GVHD): first-line and topi-
cal treatment of chronic GVHD. Biology of blood and marrow
transplantation : journal of the American Society for Blood
and Marrow Transplantation 16: 1611-1628, 2010.
422. Wolff D, Roessler V, Steiner B, Wilhelm S, Weirich V, Bren-
moehl J, Leithaeuser M, Hofmeister N, Junghanss C, Casper J,
Hartung G, Holler E, and Freund M. Treatment of steroid-
resistant acute graft-versus-host disease with daclizumab and
etanercept. Bone marrow transplantation 35: 1003-1010, 2005.
423. Wolin KY, Ruiz JR, Tuchman H, and Lucia A. Exercise in
adult and pediatric hematological cancer survivors: an inter-
vention review. Leukemia 24: 1113-1120, 2010.
424. Wu CJ, and Ritz J. Induction of tumor immunity following
allogeneic stem cell transplantation. Advances in immunology
90: 133-173, 2006.
425. Wynn TA, Cheever AW, Jankovic D, Poindexter RW, Caspar P,
Lewis FA, and Sher A. An IL-12-based vaccination method for
preventing fibrosis induced by schistosome infection. Nature
376: 594-596, 1995.
112 •   Graft-versus-host disease and exercise
EIR 21 2015
426. Wysocki CA, Burkett SB, Panoskaltsis-Mortari A, Kirby SL,
Luster AD, McKinnon K, Blazar BR, and Serody JS. Differen-
tial roles for CCR5 expression on donor T cells during graft-
versus-host disease based on pretransplant conditioning. Jour-
nal of immunology 173: 845-854, 2004.
427. Wysocki CA, Jiang Q, Panoskaltsis-Mortari A, Taylor PA,
McKinnon KP, Su L, Blazar BR, and Serody JS. Critical role
for CCR5 in the function of donor CD4+CD25+ regulatory T
cells during acute graft-versus-host disease. Blood 106: 3300-
3307, 2005.
428. Wysocki CA, Panoskaltsis-Mortari A, Blazar BR, and Serody
JS. Leukocyte migration and graft-versus-host disease. Blood
105: 4191-4199, 2005.
429. Xu Y, Flies AS, Flies DB, Zhu G, Anand S, Flies SJ, Xu H,
Anders RA, Hancock WW, Chen L, and Tamada K. Selective
targeting of the LIGHT-HVEM costimulatory system for the
treatment of graft-versus-host disease. Blood 109: 4097-4104,
2007.
430. Xun CQ, Thompson JS, Jennings CD, Brown SA, and Widmer
MB. Effect of total body irradiation, busulfan-cyclophos-
phamide, or cyclophosphamide conditioning on inflammatory
cytokine release and development of acute and chronic graft-
versus-host disease in H-2-incompatible transplanted SCID
mice. Blood 83: 2360-2367, 1994.
431. Yano K, Kanie T, Okamoto S, Kojima H, Yoshida T, Maruta I,
Dohi H, Morishita Y, Ozawa K, Sao H, Sakamaki H, Hiraoka
S, Imoto S, Morishima Y, and Kodera Y. Quality of life in adult
patients after stem cell transplantation. International journal of
hematology 71: 283-289, 2000.
432. Yi T, Chen Y, Wang L, Du G, Huang D, Zhao D, Johnston H,
Young J, Todorov I, Umetsu DT, Chen L, Iwakura Y, Kandeel
F, Forman S, and Zeng D. Reciprocal differentiation and tis-
sue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-
versus-host disease. Blood 114: 3101-3112, 2009.
433. Yi T, Zhao D, Lin CL, Zhang C, Chen Y, Todorov I, LeBon T,
Kandeel F, Forman S, and Zeng D. Absence of donor Th17
leads to augmented Th1 differentiation and exacerbated acute
graft-versus-host disease. Blood 112: 2101-2110, 2008.
434. Zaja F, Bacigalupo A, Patriarca F, Stanzani M, Van Lint MT,
Fili C, Scime R, Milone G, Falda M, Vener C, Laszlo D,
Alessandrino PE, Narni F, Sica S, Olivieri A, Sperotto A, Bosi
A, Bonifazi F, Fanin R, and Gitmo. Treatment of refractory
chronic GVHD with rituximab: a GITMO study. Bone marrow
transplantation 40: 273-277, 2007.
435. Zeiser R, Penack O, Holler E, and Idzko M. Danger signals
activating innate immunity in graft-versus-host disease. Jour-
nal of molecular medicine 89: 833-845, 2011.
436. Zhang C, Todorov I, Zhang Z, Liu Y, Kandeel F, Forman S,
Strober S, and Zeng D. Donor CD4+ T and B cells in trans-
plants induce chronic graft-versus-host disease with autoim-
mune manifestations. Blood 107: 2993-3001, 2006.
437. Zhang Q, Raoof M, Chen Y, Sumi Y, Sursal T, Junger W, Brohi
K, Itagaki K, and Hauser CJ. Circulating mitochondrial
DAMPs cause inflammatory responses to injury. Nature 464:
104-107, 2010.
438. Zhou L, Askew D, Wu C, and Gilliam AC. Cutaneous gene
expression by DNA microarray in murine sclerodermatous
graft-versus-host disease, a model for human scleroderma. The
Journal of investigative dermatology 127: 281-292, 2007.
439. Zimmerman Z, Shatry A, Deyev V, Podack E, Mammolenti M,
Blazar BR, Yagita H, and Levy RB. Effector cells derived
from host CD8 memory T cells mediate rapid resistance
against minor histocompatibility antigen-mismatched allo-
geneic marrow grafts without participation of perforin, Fas lig-
and, and the simultaneous inhibition of 3 tumor necrosis factor
family effector pathways. Biology of blood and marrow trans-
plantation : journal of the American Society for Blood and
Marrow Transplantation 11: 576-586, 2005.
440. Zorn E, Kim HT, Lee SJ, Floyd BH, Litsa D, Arumugarajah S,
Bellucci R, Alyea EP, Antin JH, Soiffer RJ, and Ritz J.
Reduced frequency of FOXP3+ CD4+CD25+ regulatory T
cells in patients with chronic graft-versus-host disease. Blood
106: 2903-2911, 2005.
441. Zorn E, Miklos DB, Floyd BH, Mattes-Ritz A, Guo L, Soiffer
RJ, Antin JH, and Ritz J. Minor histocompatibility antigen
DBY elicits a coordinated B and T cell response after allo-
geneic stem cell transplantation. The Journal of experimental
medicine 199: 1133-1142, 2004.
